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ii. Abbreviations 
 
5-FC  5-fluorocytosine 
5-FU  5-fluorouracil 
Ad  adenovirus 
Ad3  adenovirus of serotype 3 
Ad5  adenovirus of serotype 5 
AFP  alpha-phetoprotein 
APC  adenoidal-pharyngeal-conjuctivis virus 
C4BP  C4-binding protein 
CAR  coxsackie-adenovirus receptor 
CD  cytosine deaminase 
CE  carboxylesterase 
CEA  carcinoembryonic antigen 
CIC  cancer-initiating cell 
CIK  cytokine-induced killer 
COX-2  cyclooxygenase-2 
CPT-11  irinotecan 
CSC  cancer stem cell 
CTL  cytotoxic T lymphocyte 
DC  dendritic cell 
EGF  epidermal growth factor 
FIX  coagulation factor IX 
FVII  coagulation factor VII 
FX  coagulation factor X 
GCV  ganciclovir 
GM-CSF granulocyte-macrophage colony-stimulating factor 
HCC  hepatocellular carcinoma 
HSPG  heparan sulfate proteoglycan 
HSV  herpes simplex virus 
HSV-1  herpes simplex virus type 1 
hTERT  human telomerase reverse transcriptase 
IFN  interferon 
ITR  inverted terminal repeat 
LDL  low-density lipoprotein 
mAb  monoclonal antibody 
MHC  major histocomplatibility complex 
MSCs  mesenchymal stem cells 
NK  natural killer (cell) 
OTC  ornithine transcarbamylase 
PEG  polyethylene glycol 
PKR  protein kinase R  
pRb  retinoblastoma protein 
PSA  prostate-specific antigen 
RGD  arginine-glycine-aspartic acid 
SPB  surfactant protein B 
TLR  toll-like receptor 
TK  thymidine kinase 
TNF-α  tumor necrosis factor 
Treg  regulatory T cell 
TSP  tissue spesific  promoter 
VEGF  anti-vascular endothelial growth factor 
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iii. Abstract 
 
Although the treatment of most cancers has improved steadily, only few metastatic solid 
tumors can be cured. Despite frequent responses, refractory clones often emerge and the 
disease becomes refractory to available treatment modalities. Although chemotherapeutic 
agents and radiation therapy target various cellular structures and pathways, the majority of 
them kill cancer cells through induction of apoptosis and selectivity is based mostly on more 
rapid replication of tumor cells in comparison to normal cells. As malignant cells are 
characterized by an ability to adapt to the environment, apoptosis-resistant clones frequently 
develop following standard treatment. Furthermore, resistance factors are shared between 
different treatment regimens and therefore loss of response typically occurs rapidly, and there 
is a tendency for cross-resistance between agents. Therefore, new agents with novel 
mechanisms of action and lacking cross-resistance to currently available approaches are 
desperately needed.  
Oncolytic adenoviruses, featuring cancer-selective cell lysis and spread, constitute a 
particularly interesting drug platform towards the goals of tumor specificity and the 
implementation of potent multimodal treatment regimens, and have been engineered in a 
variety of ways with the aim of improving their selectivity and efficacy. Adenoviruses allow 
rational drug development by genetic incorporation of targeting mechanisms that can exert 
their function at different stages of the viral replication cycle. In this work, we demonstrate 
the applicability of capsid-modified, transcriptionally targeted oncolytic adenoviruses in 
targeting gastric, pancreatic and breast cancer. 
A variety of capsid modified adenoviruses based on serotype 5 were tested in vitro in 
gastric and pancreatic cancer cells and fresh patient tissues for transduction specificity. 
Biodistribution analysis was done in an orthotopic gastric cancer model to confirm the 
targeting potential of capsid modified viruses in vivo. Then, the corresponding oncolytic 
viruses featuring the same capsid modifications were tested in their cell killing capacity. This 
confirmed that successful transductional targeting translated into enhanced oncolytic potential 
of the viruses. Capsid modified oncolytic viruses also prolonged the survival of tumor bearing 
orthotopic models of gastric and pancreatic cancer. Taken together, oncolytic adenoviral gene 
therapy could be a potent drug for gastric and pancreatic cancer, and its specificity, potency 
and safety can be modulated by means of capsid modification. 
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We also characterized a new intraperitoneal virus delivery method in benefit for the 
persistence of gene delivery to intraperitoneal gastric and pancreatic cancer tumors. With a 
silica implant a steady and sustained virus release to the vicinity of the tumor improved the 
survival of the orthotopic tumor bearing mice. Furthermore, silica gel-based virus delivery 
lowered the toxicity mediating proimflammatory cytokine response and production of total 
and anti-adenovirus neutralizing antibodies (NAbs). On the other hand, silica shielded the 
virus against pre-existing NAbs, resulting in a more favorable biodistribution in the 
preimmunized mice. The virus in silica implant might therefore be of interest in treating 
intraperitoneally disseminated disease. 
Cancer stem cells are thought to be resistant to conventional cancer drugs and might 
play an important role in breast cancer relapse and the formation of metastasis. Therefore, we 
examined if transcriptionally modified oncolytic adenoviruses are able to kill these cells. 
Complete eradication of putative breast cancer stem cells, suggested to reside in the 
CD44
+
CD24
-/low
 population, was seen in vitro. Furthermore, these viruses displayed 
significant antitumor activity in CD44
+
CD24
-/low
 -derived tumors in mice. These findings may 
have relevance for the elimination of cancer stem cells in humans.  
In conclusion, the results presented here suggest that the genetically engineered 
oncolytic adenoviruses have potential in destroying cancer initiating cells and in treating 
gastric and pancreatic cancers.  
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PART B 
 
REVIEW OF THE LITERATURE 
 
1. Introduction 
 
In 2002, estimated 11 million new cancer cases and 7 million cancer deaths were reported 
worldwide; nearly 25 million people living with cancer (Parkin, Bray et al. 2005). World 
population growth and ageing imply a progressive  increase in cancer burden – 15 million 
new cases and 10 million new deaths are expected in 2020 (Parkin 2001). Past decades have 
increased the knowledge of molecular background dramatically. Cancer has been revealed to 
be a disease involving dynamic changes in the genome. The foundation has been set in the 
discovery of mutations leading to inactivation of tumor suppressor genes and activation of 
oncogenes. Both classes of genes have been identified (Bishop 1996). Better understanding of 
the disease and emerging modern technologies have led to the development of more sensitive 
diagnostic methods and new therapies.  Cancer has, however, remained mostly incurable 
especially in the advanced stages when metastatic. There are more than 100 distinct types of 
cancer, and subtypes can be found within organs. Tumor cells are disrupted in distinct 
regulatory circuits, which may vary from cell to cell even within a tumor. Some of these 
circuits operate on cell-autonomous basis, some are coupled with signals that cells receive 
from within a tissue (Hanahan and Weinberg 2000). Due to the complexity of the disease, the 
great breakthrough in cancer treatment is still to come. 
Gene therapy is an exciting relatively novel approach for treating cancers resistant to 
currently available modalities. Treatment approaches are based on taking advantage of 
molecular differences between normal and tumor cells (Hemminki 2002). Suitable gene 
transfer vector is chosen based on the characteristics of the disease. Efficient vector for cancer 
treatment necessitates efficient transduction and gene expression in target cells, whereas 
sustained gene expression is subsidiary (Bauerschmitz, Barker et al. 2002). Adenoviruses are 
convenient as gene delivery vectors for cancer treatment, in which context they have been 
widely studied. Oncolytic adenoviruses utilize a straight forward means of action: Instead of 
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correcting a mutated gene in cancer cell, the whole tumor cell is killed following viral 
replication. Unfortunately, although the results in several oncolytic adenovirus cancer therapy 
trials have been encouraging in terms of safety, efficacy as a single agent is limited for several 
reasons. After intravenous administration, blood clearance and liver sequestration 
dramatically decrease the amount of virus available in the circulation. Tumor 
microenvironment further restricts viral spread. Several approaches have been taken to 
address these issues, with studies well underway to address specificity, delivery, and potency 
of adenoviruses. 
 
2. Oncolytic viruses 
 
Many viruses are known to be cancer-selective and oncolytic by nature. For instance 
adenoviruses infect quiescent cells and induce them into the S phase of the cell cycle so that 
viral replication can proceed (Van Dyke 1994). After the first round of replication, cancer 
cells are lysed and virus progeny are released to infect the neighbouring cancer cells. In 
theory, the rounds of infection and replication would continue until the whole tumor mass is 
eradicated. Normal cells are spared and thus toxicity is limited. Herpes simplex virus type 1 
(HSV-1) has natural tropism for neuronal tissue, which makes it suitable for treating brain 
tumors. HSV-1 can be directed to replicate selectively in dividing cells by mutating crucial 
virulence genes, and has been studied widely as an oncolytic agent (Varghese and Rabkin 
2002). Vaccinia represents another well characterized oncolytic agent, and has a long history 
as a smallpox vaccine. Genome size allows the insertion of  large transgenes for 
virotherapeutic purposes, and conditionally replicating deletion mutants specific for cancer 
have been developed (Thorne, Hwang et al. 2005). Porcine Seneca Valley virus is a newly 
discovered native picornavirus. In vitro and in vivo studies have proposed this virus possess 
potential for the treatment of metastatic neuroendocrine cancers (Reddy, Burroughs et al. 
2007). Other recently studied viruses with oncolytic activity include Poxvirus family member 
Myxoma (Wang, Barrett et al. 2006), vesicular stomatitis virus (Barber 2004) and Semliki 
Forest virus (SFV) (Smyth, Fleeton et al. 2005). 
The exact virus-tumor interactions leading to natural oncolytic potential are not well 
understood. It is known that most tumors are defective in interferon/protein kinase R (PKR) 
signalling, because of the anti-tumoral effects of interferon. Lack of interferon also renders 
tumor cells more susceptible to viruses. This may be one explanation which underlies the 
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natural tumor selectivity of some viruses (Balachandran and Barber 2007). Oncolytic activity 
of the Newcastle disease virus, for example, is possibly due to cancer-specific defects in the 
interferon signalling pathway (Sinkovics and Horvath 2000). 
 
2.1 Adenoviruses 
Adenoviruses infect many post-mitotic cell types and have a wide host-range. Since they 
deliver their genome to the nucleus and can replicate with high efficiency, they are good 
candidates for the expression and delivery of therapeutic genes (Russell 2000). Adenoviruses 
are currently divided into three genera with further subdivision into species A to F. The 
division of human serotypes, based mainly on immunological criteria, has historically been 
the basis of classification (Lukashok and Horwitz 1998). 
Capsid is nonenveloped and icosahedral consisting of three major proteins (figure 1): 
Hexon, penton base and a knobbed fiber, along with a number of other minor proteins, VI, 
VIII, IX, IIIa and IVa2 (Stewart, Fuller et al. 1993).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structure of the adenovirus particle. The principal components are the homotrimeric hexons on the 
faces and edges of the capsid, together with the pentons consisting of penton bases and extended fibers on the 
apices. Other capsid proteins (IIIa, VI, VIII, IX) are also called „minor components‟. There are six other 
structural components in the core, of which the five associated with the genome are shown. The remaining 
component not shown is the 23K virion protease which plays pivotal role in the assembly of the virion; adapted 
from: (Volpers & Kochanek 2004). 
 
 
The adenovirus genome consists of 36 kb double-stranded DNA. Genome is divided into 
E1A, E1B, E2A, E2B, E3 and E4 regions, which regulate the gene expression (figure 2). 
Transcripts are encoded via alternative splicing of each transcription unit to generate multiple 
products from each region (Berget, Moore et al. 1977; Berk and Sharp 1978). The infectious 
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cycle can be clearly defined into early and late phases (before and after viral DNA replication, 
respectively).  
 
 
 
Figure 2. Genomic organization of Ad5. The first Ad gene to be expressed is the immediate early E1A gene 
encoding a transactivator for the transcription of the early genes E1B, E2A, E2B, E3 and E4, as well as protein 
functions involved in cellular transformation, together with an E1B protein. Promoters are depicted by arrowheads; 
early(E) and late (L) mRNAs are depicted by thin and heavy arrows, respectively. The adenovirus major late 
promoter (MLP) is active during both the early and late phases of infection; adapted from:   (Volpers & 
Kochanek 2004). 
 
 
The early phase covers the entry of the virus into the host cell and the passage of the virus 
genome to the nucleus, followed by the selective transcription and translation of early genes 
(figure 3). The binding of virus to target cell involves high-affinity binding via the knob 
portion of the fiber to receptor, primary receptor being coxsackie-adenovirus receptor (CAR) 
(Bergelson, Cunningham et al. 1997). The exceptions are members of subgroup B, from 
which for example Ad3 binds to another, yet unidentified receptor (Stevenson, Rollence et al. 
1995). The critical recognition mechanism for CAR binding is an arginine-glycine-aspartic 
acid (RGD) motif that is exposed on the penton base (Stewart, Chiu et al. 1997) and interacts 
with cellular αvβ integrins (Wickham, Mathias et al. 1993). In addition to integrins, heparin 
sulphates, major histocompatibility complex class I α2, vascular cell adhesion molecule 1 and 
scavenger receptors have been suggested as alternative or coreceptors for species C 
adenoviruses (Jonsson, Lenman et al. 2009). Adenoviruses can also use soluble components 
in the body fluids for indirect binding to the target cells. As an example, lactoferrin is secreted 
by, for instance, neutrophils into epithelial mucosa and tear fluid and interacts with fiber 
protein, thus mediating CAR-independent binding to and infection of epithelial cells 
(Johansson, Jonsson et al. 2007). Entry of the virus proceeds via clathrin coated pit mediated 
endocytosis (Wang, Huang et al. 1998). Virus capsid is further disrupted by the proteolysis of 
the structural protein VI (Greber, Webster et al. 1996). Partially disrupted virus is then 
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transported to the nuclear membrane and the genome is passaged through the nuclear pore 
into the nucleus, where the primary transcription events take place. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The adenoviral infection pathway. Cell entry is initiated by high-affinity binding of the fiber knob 
domain to its primary receptor, CAR. CAR-binding is followed by endocytosis, mediated by penton base RGD 
interaction with cellular αvβ integrins. After endosomal lysis, viral DNA is transported to the nucleus through a 
microtubule-mediated process, and viral genes and transgenes are expressed; adapted from: (Kanerva & 
Hemminki 2005). 
 
 
Many of the early phase region (E1 through E4) products are necessary for downstream 
events in the early transcription cascade, and progression to late phase transcription. E1A both 
activates the transcription of further viral genes and manipulates the host cell physiology to 
make the environment hospitable for viral replication, with resultant transcription and 
translation of the late genes. One of the major functions of the E1B proteins is to counteract 
apoptosis (Rao, Debbas et al. 1992; Yew and Berk 1992). E2 gene products provide the 
machinery for the replication of virus DNA (Hay, Freeman et al. 1995), whereas E3 genes 
code for several proteins that suppress host immunodefence mechanisms (Russell 2000). 
Products of E4 gene function in concert with E1A and E1B to create a cellular environment 
permissive for efficient expression and processing of viral gene products (Goodrum and 
Ornelles 1999), leading to an assembly of the structural proteins in the nucleus, and the 
maturation of the infectious virus. The early phase in a permissive cell can take about 6±8 h 
(depending on the number of extraneous factors), while the late phase is normally much more 
rapid, yielding new virus in another 4±6 h.  
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3. Adenoviruses as gene transfer vehicles 
 
Gene therapy for cancer has generated increasing interest for over two decades and 
experimental and clinical investigations are under way. In general, it comprises insertion of 
nucleic acids into cells of an individual to treat a disease.  Therapeutic gene supplements a 
defective gene with a functional one, or encodes RNA or protein with therapeutic function. 
Whereas the first gene therapy trials were based on gene replacement for the treatment of 
monogenetic disorder, today only less than 10% of studies utilize this approach. Viral vectors 
are by far the most popular gene therapy approach, adenoviruses being the most commonly 
used viral vectors (25 % of clinical trials) (Edelstein, Abedi et al. 2007), while 75 % of 
adenoviral gene therapy trials are for the treatment of cancer. Based on the complex nature of 
cancer, gene therapy technologies to treat cancer are very heterogeneous, as demonstrated by 
a variety of used concepts such as immunomodulation, suicide gene therapy (i.e., transfer of 
the cDNA of a prodrug converting enzyme), replacing a faulty gene with a functional one, 
viral oncolysis, antiangiogenic and antiproteolytic gene therapy, or the delivery of drug 
resistance genes into hematopoietic precursor cells (Templeton 2009). 
Adenoviruses possess many characteristics that make them a vector of choice for 
oncolytic virotherapy. They have a lytic replication cycle, their non-integrating genome stays 
episomal in the host cell, stable particles, an efficient gene transfer machinery and capability 
to infect both proliferating and nonproliferating cells. They can be produced in high titers and 
have for long been known to be oncolytic by nature (Huebner, Rowe et al. 1956). The vectors 
used for adenoviral gene therapy are derived from the subgroup C. Wild-type viruses from 
this subgroup cause mild upper respiratory tract infections, which resolves uneventfully in 
healthy individuals. Adenoviruses used in gene therapy are usually based on serotype 5 
(Ad5). 
Several regions of adenovirus genome can be deleted to accommodate up to 10 kb of 
foreign DNA (figure 4). Recombinant genomes with the size of 105% of 36 kb or less are 
efficiently incorporated into virus capsids resulting in stable viruses (Bett, Prevec et al. 1993). 
In many of the viruses used in trials, majority of the E1A and E1B regions are deleted to 
prevent virus replication. This also gives room for transgenes, such as therapeutic or suicide 
genes for enhanced oncolytic effect. In first generation adenoviruses, the E1A is replaced with 
a therapeutic transgene. Second generation adenoviruses typically have deletions either in E2 
or E4, and deleted E1 and E3 regions, allowing to accommodate even larger or more 
transgenes. Helper dependent, also known as gutless, represent the third generation vectors. In 
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these vectors all viral genes except the inverted terminal repeats (ITRs) and the packaging 
signal have been deleted to further decrease immunogenicity and increase genetic payload 
(Shen 2006). 
 
 
 
Figure 4. Different types of Ad5-derived vectors The first-generation vectors are based on the substitution of the E1 
gene region by the transgene and are thus nonreplicating. The first-generation vectors can have an additional deletion 
in E3 which is dispensable for viral replication in cell culture. The second-generation Ad vectors are characterized by 
additional deletions. Third is shown a high-capacity vector, which is devoid of all coding viral genes, but contains only 
the ITRs and the packaging signal (Ψ), and can accommodate up to 36 kb of non-viral DNA. Fourth is shown one type 
of conditionally replicative Ad vector, characterized by a deletion in the gene encoding the 55 kDa E1B protein which 
normally binds to and inactivates p53, thereby activating the cell cycle. These vectors should productively infect and 
lyse p53-negative tumor cells, but not normal p53-positive cells; adapted from: (Volpers & Kochanek 2004). 
 
 
3.1 Transductional targeting of adenoviruses 
The capacity of an Ad5 vector to infect a given cell is dictated by the CAR- and integrin –
expression levels of the cell. It has been shown that cells expressing both receptors below a 
certain threshold level are refractory to Ad infection (Freimuth 1996). A number of cell types 
such as endothelial, smooth muscle cells, differentiated airway epithelium cells, lymphocytes, 
fibroblasts and hematopoietic cells demonstrate either complete or partial resistance to Ad 
infection (Curiel and Douglas 2002). Adenovirus gene therapy vectors have also been 
reported to be incapable of transducting germ cells even with high doses (Gordon 2001). 
Importantly, many types of tumor cells express CAR at marginal or even undetectable levels 
and are thus Ad-refractory (Hemmi, Geertsen et al. 1998), leading to the development of 
several methods to improve poor infectivity due to low CAR expression (Pong, Lai et al. 
2003). Histone deacetylase inhibitor trichostatin A is an upregulator of CAR expression, and 
has been used to improve adenoviral infectivity to low CAR cells (Kitazono, Goldsmith et al. 
2001; Goldsmith, Kitazono et al. 2003). In combination with oncolytic adenovirus dl520 
(ONYX-015) trichostatin had a significant effect on the replication and cytotoxicity (Bieler, 
Mantwill et al. 2006). Two distinct approaches have been employed to transductionally target 
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adenovirus vectors (figure 5): (1) targeting achieved via structural manipulation of the capsid 
by genetic means (Wickham, Tzeng et al. 1997), and (2) adapter molecule-based targeting. 
According to literature, there is some evidence suggesting that CAR may not be the primary 
Ad receptor in vivo. First, removal of the CAR-binding capacity of Ad vectors does not 
change their biodistribution in mice (Alemany and Curiel 2001). Secondly, mRNA expression 
of CAR correlates poorly with in vivo tropism of Ad vectors (Tomko, Xu et al. 1997). Third, 
CAR has been reported to have another relevant function in the fiber-CAR interaction, which 
is to facilitate viral escape from the site of infection (Walters, Freimuth et al. 2002). 
 
 
 
Figure 5. Adenovirus targeting. Virus can be genetically or physically modified to retarget binding from primary 
CAR receptor to alternative receptors expressed on target cells. In the middle, adenovirus knob is pseudotyped 
(changed to another serotype), or modified to display a peptide, resulting in altered receptor tropism. On the 
right, transductional targeting is achieved by utilizing bispesific adapter molecules that block interaction with 
CAR and redirect the virus to a novel receptor; adapted from:  (Hakkarainen, Kanerva et al. 2005). 
 
 
3.1.1 Transductional targeting through capsid modification 
One approach to totally change transductional profile and to restrict broad natural tropism of 
an adenovirus is to genetically modify the capsid structure by ablating coxsackievirus-
adenovirus receptor, αv integrin, and heparan sulfate binding. This has been achieved through 
mutating FG loop in the fiber knob, deleting RGD motif of the penton base, and substituting 
the fiber shaft domain with that from serotype 35. Such triple-mutant adenovirus has been 
shown to display reduced in vivo tissue transduction and toxicity (Koizumi, Kawabata et al. 
2006). This could offer a platform for subsequent retargeting of the the virus.  
 Adenovirus capsid can be retargeted to interact with other receptors than CAR (figure 
6). For example, introducing an RGD-containing peptide in the HI loop of the fiber knob 
targets the virus to cells expressing αvβ- integrins (Pasqualini, Koivunen et al. 1997; 
Wickham, Tzeng et al. 1997; Grill, Van Beusechem et al. 2001; Fueyo, Alemany et al. 2003).  
αvβ- integrins are overly expressed in many cancers, as are heparan sulfates. They have been 
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targeted using adenoviruses with a COOH-terminal polylysine tail (Wu, Seki et al. 2002; 
Yotnda, Zompeta et al. 2004).  
 
Figure 6. Adenovirus capsid modifications for transductional targeting. A, Ad5 “wild type” capsid with the 
default serotype 5 fiber binds to CAR receptor. B, 5/3 chimeric fiber targeted to serotype 3 yet unidentified 
receptor. C, polylysine motifs of different lengths in the C terminus of the knob bind to HSPG‟s. D, arginine-
glycine-aspartic acid (RGD)-motif in the HI-loop of the fiber targeted to αvβ-integrins. 
 
 
CAR deficiency has also been circumvented by serotype switching. Ad5/3 is chimeric 
serotype 5 adenovirus featuring serotype 3 (Ad3) knob, retargeting it to bind to Ad3 receptor 
(Kanerva, Mikheeva et al. 2002). Taking the "directed evolution" approach, viral diversity 
was increased by pooling an array of serotypes, then passaging the pools under conditions that 
invite recombination between serotypes. These highly diverse viral pools were then placed 
under stringent directed selection to generate and identify highly potent agents. ColoAd1, a 
complex Ad3/Ad11p chimeric virus, was the initial oncolytic virus derived by this 
methodology. This first described non-Ad5-based oncolytic Ad, is 2-3 logs more potent and 
selective than the parent serotypes or the clinically advanced oncolytic Ad, ONYX-015, in 
vitro (Kuhn, Harden et al. 2008). In addition to serotypes 3 and 11, also serotype 35 fiber has 
been used in replacement of Ad5 fiber for enhanced oncolysis. Ad5 vectors containing Ad35 
fibers (Ad5/35) use CD46 as a receptor for infection of cells, which solves the problem with 
low CAR on cancer cells (Gaggar, Shayakhmetov et al. 2003). Adenovirus serotype 35 is also 
less prone to unspecific virus sequestration by blood components, including coagulation 
factor X (Liu, Wang et al. 2009; Wang, Li et al. 2009). 
Initial attempts to reduce liver tropism were based on the hypothesis that CAR- and 
integrin-based interactions were required for liver transduction in vivo, and that fiber protein 
is one important structural determinant of liver tropism. For example, shortening of the native 
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fiber shaft domain of the Ad5 fiber (Vigne, Dedieu et al. 2003) or replacement of the Ad5 
shaft with the short Ad3 shaft domain (Breidenbach, Rein et al. 2004) has been shown to 
attenuate liver uptake following intravenous delivery. Short-shafted Ads are unable to infect 
liver cells through CAR or through the KKTK shaft motif (Shayakhmetov, Li et al. 2004). 
Due to these features, they are not taken up by liver cells and are probably degraded within 
the sinusoids. In related work, the role of a putative heparan sulfate proteoglycan (HSPG)-
binding motif, KKTK, in the third repeat of the native fiber shaft was examined. Replacement 
of this motif with an irrelevant peptide sequence reduced reporter gene expression in the liver 
by 90%. This was also the first indication of the importance of HSPG as an Ad receptor in 
vivo (Smith, Idamakanti et al. 2003). A recent report describes systemic delivery of αvβ-
targeted Ad to result in improved tumor uptake and reduced liver accumulation and 
hepatotoxicity in mice (Coughlan, Vallath et al. 2009). It remains uncertain, however, 
whether the above mentioned in vivo data has significance in human applications. 
 
3.1.2 Adapter-based targeting 
The majority of current adapter-based adenovirus targeting approaches incorporate the two 
mandates of delivery targeting, that of ablation of native CAR-dependent Ad tropism to 
restrict gene delivery exclusively to target cells, and formation of a novel tropism to 
previously identified cellular receptors. The formation of a molecular bridge between the 
adenovirus vector and the cell surface receptor constitutes the adapter-based concept of 
transductional targeting (figure 5). Bispecific adapter molecules include bi-specific antibodies 
(Korn, Nettelbeck et al. 2004), cell-selective ligands such as folate (Douglas, Rogers et al. 
1996) and chemical conjugates (Reynolds, Zinn et al. 2000). Chemically conjugated bispesific 
moieties consisting of a Fab fragment and a natural ligand specific for cell surface receptor 
have an advantage that a variety of ligands, including vitamins, growth factors, antibodies, 
and peptides, can be chemically conjugated to the anti-knob Fab fragment to redirect Ad 
binding (Glasgow, Everts et al. 2006). However, the chemical conjugation results in a 
heterogeneous population of molecules. Moreover, the yield of appropriately conjugated 
bispesific molecules can be low (Curiel and Douglas 2002). 
 In recognition of the disadvantages associated with chemical conjugation strategies, 
bispesific targeting moieties have been generated in the form of recombinant fusion proteins 
(Korn, Nettelbeck et al. 2004). This permits the expression and purification of a homogenous 
population of retargeting molecules. The principle of bispesific proteins is that one site of the 
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protein is directed against Ad capsid protein, while a second site is specific for a cell surface 
molecule. This can be achieved by genetically fusing extracellular domain of CAR to a 
receptor-targeting moiety, yielding a truly targeted vector that blocks CAR binding: Once 
complexed with CAR-ligand fusion protein, an Ad vector will not be able to bind to its 
primary receptor. Utilizing this approach, a truncated, soluble form of CAR, sCAR, was fused 
to EGFR, and the soluble CAR-EGF fusion protein was expressed in insect cells using a 
baculovirus expression system. The bispesific fusion protein mediated EGFR-specific, CAR-
independent Ad infection of target cells (Dmitriev, Kashentseva et al. 2000). Overall, adapter-
based targeting studies provide compelling evidence that adenovirus tropism modification 
augments gene delivery to CAR-deficient cells in vitro. Adapter-targeted vectors have also 
performed well in vivo, although data so far are limited (Glasgow, Everts et al. 2006). 
  
4. Polymers and vehicles in adenoviral gene delivery 
 
As partial solution to adenovirus induced immune response and liver sequestration could be a 
disguise, such as carrier cells or coating agents. Adding anti-cancer drugs to implantable 
delivery matrix, such as silica-based sol-gel polymer, is one promising strategy for modifying  
biodistribution, reducing drug toxicity and thus improving the therapeutic efficacy of anti-
tumor agents (Quintanar-Guerrero, Ganem-Quintanar et al. 2009). The manufacturing process 
is based on inorganic polymerization in conditions compatible with biologicals, allowing the 
association of mineral phases with organic materials. In the process, the sol (solvent) evolves 
towards the formation of a gel-like diphasic system (sol-gel polymerization). Drugs, proteins, 
cells and viruses can be immobilized into sol-gel polymers without loss of biological activity 
(Coradin, Boissiere et al. 2006). By changing the sol-gel synthesis parameters, drug 
concentration, size of the device and the dissolution rate can be adjusted according to purpose 
of use (Viitala, Jokinen et al. 2007). As examples of anti-cancer drugs, silica sol-gel implant 
has been studied as a delivery device for cisplatin (Czarnobaj and Lukasiak 2004) and 
doxorubicin (Prokopowicz 2007). The authors hypotize that higher local drug concentration, 
longer target exposure to the drug and spontaneous degradation of the implant might lead to 
reduced toxicity and improved delivery to the tumor site. The same hypotheses applied to our 
work, where we demonstrated that silica implants can be successfully used in intraperitoneal 
delivery of oncolytic adenoviruses in vivo, resulting in prolonged survival of intraperitoneal 
orthotopic tumor-bearing mice. Further, delivering the virus in silica had favorable effect on 
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anti-adenovirus immune response (III-IV). Another example of a polymer used for coating 
adenoviruses to disguise the virus from the immune system is polyethylene glycol (PEG).  
PEGylation has been reported to reduce blood clearance rate (Freytag, Stricker et al.). 
However, this procedure also reduces infectivity (Alemany, Suzuki et al. 2000).  
Cytokine-induced killer (CIK) cells are known to home to and destroy tumors. CIK 
cells can be isolated from blood stream, infected with virus, and systemically readministered. 
Oncolytic vaccinia viruses and CIK cells have been shown to be synergistic in tumor cell 
killing in tumor-bearing mice (Thorne, Negrin et al. 2006). Mesenchymal stem cells (MSCs) 
have also been suggested to have inherent tumor tropism. Using MSCs as carriers, 
intravenously injected oncolytic adenoviruses were released into advanced orthotopic breast 
and lung tumors, and survival of the mice was increased. When the same dose of virus was 
injected intravenously without MSCs, liver transduction was prevalent (Hakkarainen, Sarkioja 
et al. 2007). Also intravenously injected tumor cells have been tested as carriers for tumor 
targeting in vivo, and were found to home to metastases (Garcia-Castro, Martinez-Palacio et 
al. 2005). The authors speculate this approach to be feasible also for targeting oncolytic 
viruses to tumors.  
 
5. Transcriptional targeting of Ads 
 
5.1 Type 1 oncolytic adenoviruses 
Transductional targeting is not enough for achieving a potent, tumor-specific oncolytic virus. 
There is also need for controlled replication in cells. Transcomplementational approach for 
transcriptional targeting takes advantage of the fact that Ad infection and oncogenic 
transformation induce similar signalling cascades in eukaryotic cells: A number of the most 
critical early transcript functions of adenovirus (such as cell cycle deregulation and inhibition 
of apoptosis) are often complemented by the deregulated states associated with tumor cell 
differentiation (Yew and Berk 1992; Lukas, Muller et al. 1994; Han, Modha et al. 1998). 
These points within the adenoviral life cycle may be transcriptionally targeted to limit 
adenoviral replication preferentially to tumor cells. Partial deletion will impair replication 
potency in normal cells, whereas in malignant cells deletion will be transcomplemented by 
distinct cellular deregulated pathways, allowing productive replication (figure 7) (Kanerva 
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and Hemminki 2005). The loss-of function mutated adenoviruses that need 
transcomplemetation from cancer cells to replicate are called type I oncolytic adenoviruses. 
 
 
Figure 7. Conditionally replicating adenoviruses are 
genetically modified to multiply only in cancer cells. 
A, infection of tumor cells results in replication, 
oncolysis (cell killing), and subsequent release of 
virus progeny. The new generation of viruses will 
then infect neighbouring cancer cells, leading to 
cycles of replication and lysis of malignant cells 
within the tumor.  B, normal cells are spared due to 
lack of replication; adapted from: (Kanerva & 
Hemminki 2005). 
 
 
One widely used transcomplementational 
approach is based on the knowledge of most 
of the advanced human tumors being 
deficient in retinoblastoma/p16 pathway 
(Sherr 1996; Hernando, Nahle et al. 2004). Δ24-mutated adenoviruses, such as Ad5-Δ24, 
have 24 bp deletion in constant region 2 of E1A, in which the pRb binding domain resides. 
Via this domain, wild-type E1A binds to and activates pRb, required for replication in normal 
cells. Δ24 is complemented by inactivation of pRb, enabling virus replication selectively in 
cancer cells (Fueyo, Gomez-Manzano et al. 2000; Heise, Hermiston et al. 2000).  
The first and most studied oncolytic adenovirus dl1520 (ONYX-015) carries two 
mutations in the gene coding for the E1B-55 kDa protein. One purpose of this protein is 
binding and inactivation of cellular tumor suppressor p53, which is thought to respond to 
DNA damage by inducing cell cycle arrest or apoptosis. For this reason, tumors lacking p53 
respond poorly to radiation or chemotherapy, and majority of human tumors are p53 mutated 
(Bischoff, Kirn et al. 1996). E1B-55 kDa mutated ONYX-015 can replicate in and lyse p53-
deficient human tumor cells, but not cells with functional p53. Tumor cells that support 
ONYX-015 replication may do so by providing the function of E1B in late viral RNA export 
from the nucleus, allowing the virus to replicate selectively in tumor cells without normal p53 
protein or with a deficient p53 pathway (O'Shea, Johnson et al. 2004). The same authors 
subsequently reported resistant tumor cell lines failing to provide the RNA export functions of 
E1B-55K necessary for ONYX-015 replication; viral 100K mRNA export being necessary for 
host protein shutoff. However, heat shock rescues late viral RNA export and renders 
refractory tumor cells permissive to ONYX-015. Thus, heat shock and late adenoviral RNAs 
23 
 
may converge upon a common mechanism for their export (O'Shea, Soria et al. 2005). 
Interestingly, this was hypotized to explain why patients with virus induced fever getting no 
antipyretic drugs showed enhanced response in H101 clinical trial (virus similar to ONYX-
015) (Yu and Fang 2007). Of note, replication of ONYX-015 is severely impeded compared 
to wild type virus, probably resulting from a loss of E1B-55 kDa protein function for the late 
virus mRNA transcription (Harada and Berk 1999). Another shortage involves replication in 
some cultured cells lacking p53 mutations. Loss of E1B-55K leads to the induction, but not 
the activation, of p53 in ONYX-015-infected primary cells, and consequently replication in 
primary cells is not restricted (Goodrum and Ornelles 1998). 
Adenovirus dl331 contains a 29-bp deletion in the coding region of VAI gene as a 
conditionally replicative oncolytic adenovirus for Ras-activated tumors. The selectivity of this 
virus stems from the inability of dl331 to block the activation of the double-stranded RNA-
activated protein kinase (PKR) and, therefore, to prevent cellular anti-viral response. 
Oncogenic Ras also induces an inhibitor of PKR (Cascallo, Capella et al. 2003; Wang, Xue et 
al. 2005).  
Replication-deficient E1A mutant adenovirus mutant dl520 contains an 11-bp deletion 
removing the 13S donor splicing junction and resulting in the loss of the E1A protein (Haley, 
Overhauser et al. 1984). This virus replicates efficiently and exhibits oncolytic potential in 
multidrug-resistant cells with nuclear localization of the human transcription factor YB-1, 
which binds to the adenoviral late E2 promoter resulting in E1A independent replication 
(Bieler, Mantwill et al. 2006). 
 
5.2 Type II oncolytic adenoviruses 
In oncolytic adenoviruses, the anti-tumour effect is caused by the replication of the virus per 
se and replication must be restricted to tumour cells to protect normal tissues from damage. 
Tissue-specific promoters (TSPs) represent a powerful tool for decreasing the toxicity of 
cancer gene therapy to normal tissues and have previously been utilised for specific mutation 
compensation or delivery of prodrug-converting enzymes (Hardcastle, Kurozumi et al. 2007). 
However, TSPs can also be tumor specific promoters used for controlling crucial viral 
replication regulators and consequent restriction of replication to tumor cells. This class of 
Ads are called type II oncolytic adenoviruses. Since the size of a candidate promoter construct 
is restricted by the packaging capacity of adenoviral virions for DNA, large or multiple 
promoter insertions may require deletions of viral sequences, such as the viral promoter to be 
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replaced. This strategy also deletes unwanted internal control mechanisms. Minimizing the 
promoter size is also advantageous for enabling insertion of therapeutic genes into viral 
genome for improved therapeutic efficacy. Other sequences, not essential for viral replication, 
can also be deleted. Viral genes that ensure optimal viral spread should be retained 
(Nettelbeck 2008). In the context of TSPs, tight promoter control gained specificity, rather 
than strong activity in the induced state, is critical (Hitt and Graham 1990).  
E1A, being the master regulator of replication, offers the first choice to control Ad replication 
with TSPs. The first TSP driven oncolytic adenovirus was created from a serotype 5 
adenovirus by placing human prostate-specific antigen (PSA) based promoter to drive E1A, 
thereby creating a prostate-specific virus, CN706 (Rodriguez, Schuur et al. 1997). In another 
study, melanoma specific oncolysis was achieved with melanoma differentiation marker 
tyrosinase enhancer/promoter controlling E1A. This was a Ad5-Δ24 based oncolytic virus 
(Nettelbeck, Rivera et al. 2002). Oncolytic adenovirus OV798 in turn utilized human 
carcinoembryonic antigen (CEA) promoter. In this virus, CEA-driven E1A tightly controls 
gene expression and viral replication in CEA-overexpressing colon cancer cells, which also 
translated into survival benefit in human colon tumor xenograft bearing mice (Li, Chen et al. 
2003). E1A was placed under control of alpha-phetoprotein (AFP) promoter to create 
oncolytic adenovirus CV890 specific to hepatocellular carcinoma (HCC). In combination 
with doxorubicin, CV890 eliminated distant human liver tumors in HCC xenograft bearing 
mice (Li, Yu et al. 2001). Other examples of cancer specific promoter controlled replication 
include melanoma specific replication achieved with tyrosinase and hTERT promoters 
(Nettelbeck, Rivera et al. 2002; Peter, Graf et al. 2003), and cyclooxygenase-2 (Cox-2) 
promoter targeting for pancreatic cancer (Yamamoto, Davydova et al. 2003). 
In addition to E1A gene, TSPs have been placed to control E1B, E2 and E4 (Nettelbeck 
2008). By replacing the E4 promoter with the promoter for surfactant protein B (SPB), 
oncolytic adenovirus specific for alveolar and bronchial cancer cells was created. SPB 
promoter activity is restricted in the adult to type II alveolar epithelial cells and bronchial 
epithelial cells. In addition this virus had two E1A mutations, which made it replicate within 
and destroy only alveolar and bronchial cancer cells (Doronin, Kuppuswamy et al. 2001). 
Replication of oncolytic adenovirus VRX-009 is restricted to cells with a deregulated wnt 
signal transduction pathway by replacement of the wild-type Ad E4 promoter with a synthetic 
promoter consisting of five consensus binding sites for the T-cell factor transcription factor 
(Toth, Djeha et al. 2004). Cancer cell selective replication of ONYX-411 in turn resulted from 
Δ24 for pRb-selectivity, which was further enhanced by the replacement of the viral E1A and 
25 
 
E4 promoter regions with the human E2F1 gene promoter. The oncolytic activity of ONYX-
411 is not limited to a particular tumor type. The combination of these attributes resulted in 
selective tumor cell killing both in vitro and in vivo (Johnson, Shen et al. 2002). 
Adenoviral replication can also be tightly directed by controlling adenoviral E1A and 
E4 genes simultaneously with a single enhancer. This was achieved by creating a prostate 
cancer specific adenovirus with PSES enhancer controlling adenovirus E1A and E4 gene 
expression. This chimeric enhancer contains enhancer elements from prostate-specific antigen 
(PSA) and prostate-specific membrane antigen (PSMA) genes that are prevalently expressed 
in androgen-independent prostate cancers (Li, Zhang et al. 2005). Colon cancer targeted 
oncolytic adenovirus was developed to express the viral E1B and E2 genes from promoters 
controlled by the Tcf4 transcription factor. Tcf4 is constitutively activated in virtually all 
colon tumors by mutations in the adenomatous polyposis coli and beta-catenin genes, and is 
constitutively repressed in normal tissue (Brunori, Malerba et al. 2001). In another study, both 
E1 and E4 regions were controlled by a synthetic tyrosinase enhancer/promoter specific for 
melanocytes in melanoma-targeted oncolytic adenoviruses (Banerjee, Rivera et al. 2004).  
 
6. Armed oncolytic adenoviruses 
 
When replication-mediated oncolysis is the only means of tumor eradication, the efficacy of 
virotherapy can be limited. Virus induced inflammation in the tumor microenvironment also 
needs to be taken into account. Tumor microenvironment, being heterogeneous, hypoxic and 
compartmentalized, holds many obstacles for the efficient spreading of the virus. Although 
tumor hypoxia is known to limit group C adenovirus (serotype 5) replication, the expression 
level of  CD46, a receptor some group B adenoviruses, is not altered in hypoxic conditions 
(Shen, Bauzon et al. 2006). Thus, hypoxic conditions might favour Ad5 vectors that are 
modified to favour receptors other than CAR, such as Ad5/3 fiber chimera binding to Ad3 
receptor. Viruses can also be transductionally targeted to tumor matrix components, such as 
vascular endothelium. Fibroblast growth factor-2-retargeted adenovirus has been shown to 
selectively transduct primary glioblastoma multiforme endothelial cells (Gupta, Wang et al. 
2006). It may in occasions be feasible to also transcriptionally target the virus to other than 
cancer cells in the tumor. Oncolytic adenoviruses have been transcriptionally targeted with 
high specificity to dividing endothelial cells within a tumor. This has been done by utilizing 
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regulatory elements shown to be highly overexpressed in angiogenic endothelial cells 
(Savontaus, Sauter et al. 2002).  
 Viral vectors can further be weaponed with therapeutic transgenes affecting tumor 
vasculature or matrix. Antiangiogenic treatments include soluble vascular endothelial growth 
factor (VEGF) receptors and antibodies that can be expressed by adenovirus. Such soluble 
VEGF receptor producing vector has been reported to result in pronounced tumor growth 
inhibition when injected intravenously or intratumorally into mice (Kuo, Farnebo et al. 2001; 
Thorne, Tam et al. 2006). Antiantiogenic soluble Flt-1 expression from oncolytic adenovirus 
has also been shown to reduce tumor growth and prolong the survival in mice (Zhang, Zou et 
al. 2005). Protease expressing viruses can be used for targeting tumor stroma. Oncolytic 
adenovirus encoding relaxin, a matrix-degrading protein, has been reported to enhance viral 
spread without causing significant toxicity (Kim, Lee et al. 2006). Tumor stromal matrix 
targeted human matrix metalloproteinase-8 gene delivery has been shown to increase 
oncolytic activity of replicating adenovirus (Cheng, Sauthoff et al. 2007). Degrading agents 
can also be coadministered with the virus. Coadministration of matrix-modifying 
metalloproteinases and bacterial collagenase have been shown to improve distribution and 
efficacy of oncolytic vectors (McKee, Grandi et al. 2006; Mok, Boucher et al. 2007) 
Suicide gene therapy involves the tumor-targeted delivery of genes encoding enzymes 
that convert systemically delivered, innocuous prodrugs into toxic metabolites. This results in 
a high concentration of toxic product intratumorally, thereby avoiding the systemic toxicity 
often associated with conventional chemotherapy. Arming oncolytic viruses with genes 
encoding prodrug-converting enzymes yield enhanced anticancer efficacy by combining the 
effects of oncolytic replication and local prodrug activation. Examples of suicide gene 
delivery approaches include herpes simplex type 1 thymidine kinase (HSV-1 TK)/ganciclovir 
(GCV) and Escherichia coli cytosine deaminase (CD)/5-fluorocytosine (5-FC) therapy. HSV-
1 TK phosphorylates GCV, converting it to a nucleotide analog that inhibits DNA synthesis, 
while CD converts 5-FC to its highly toxic metabolite, 5-FU. The combination of CD and 
HSV-1 TK gene delivery is an example of doublesuicide gene therapy. When both of the 
respective prodrugs (5-FC + GCV) were administered, therapeutic outcome was dramatically 
improved (Rogulski, Wing et al. 2000). Replication-competent adenovirus-mediated double 
suicide gene therapy has also shown promise in combination with radiation therapy in an 
orthotopic mouse prostate cancer model (Rogulski, Wing et al. 2000; Freytag, Paielli et al. 
2002). Suicide gene therapy has also been utilized in the context of Δ24-type oncolytic 
adenovirus Ad5-Δ24.E3-sCE2, which utilizes prodrug converting enzyme 
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carboxylesterase/irinotecan (CE/CPT-11) system. Administrated CPT-11 is converted by CE 
into much more potent SN-38, which in this case augmented the cytotoxicity of the virus in 
colon cancer cells (Oosterhoff, Pinedo et al. 2005). ONYX-015-based replicating adenovirus 
has also been armed with CE/CPT-11 system. Here, cytotoxicity of CE-expressing virus was 
significantly enhanced in the presence of the prodrug, and combination treatment of CE-
expressing virus and CPT-11 enhanced survival of tumor-bearing mice (Stubdal, Perin et al. 
2003). 
 
7. Immune response 
 
Even though the results from clinical trials have been encouraging in terms of safety, there are 
downsides that need to be taken into account. Immune system has evolved to efficiently and 
rapidly recognize adenoviruses as pathogens in an innate and adaptive manner (Prestwich, 
Errington et al. 2009). Immune response is triggered by virus interaction with leukocytes, 
endothelial and epithelial cells. Tissue macrophages are derived from monocytes in the blood 
stream. Once making their way to the tissue, they develop into different phagocytic cell 
populations, which efficiently clear virus from the blood stream after systemic injection. 
These cells, along with activated dendritic cells (DCs) in the spleen, have an important role in 
provoking virus-induced inflammatory response (Muruve 2004). 
The combined innate and adaptive response upon natural Ad-infection most 
commonly results in Ad-clearance and life-long immunity in the majority of hosts (Lenaerts, 
De Clercq et al. 2008). High immunogenicity of adenovirus remains difficult to classify either 
as an advantage or disadvantage. The immune system could decrease the efficacy of the 
vector, and it may prevent the spread to organs, which may on the other hand contribute to 
safety. In the case of cancer immunotherapy, virus-induced immune response is utilized to 
synergize with anti-tumor activity of the virus. Inflammatory response is optimal for antigen 
presentation and helps to reveal the hidden tumor antigens to dendritic cells (Prestwich, 
Harrington et al. 2008). Activation of tumor-antigen-specific T cells would thereby create a 
danger signal triggering not only anti-virus but also anti-tumor immunity (Tuve, Liu et al. 
2009). The main concern with adenoviral gene therapy is the possibility of provoking a severe 
immune and inflammatory response, as was tragically exemplified in the case of a death of a 
patient with ornithine transcarbamylase (OTC) deficiency who participated in a Phase I study 
of gene therapy. The vector used for this trial was based on human adenovirus type 5, deleted 
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in E1 and E4. In this case, massive cytokine response and disseminated intravascular 
coagulation were reported (Raper, Chirmule et al. 2003). Despite this unfortunate case, it is 
noteworthy that 16 000 patients treated with adenoviral gene therapy have proven adenovirus 
to have a good safety profile compared to most conventional therapies.  
 
7.1. Innate immune response 
Innate immunity is the first line of defence against infections (figure 8). Unlike adaptive 
immunity, the innate response is mediated by the adenovirus particle and does not necessarily 
require viral transcription: Interaction of the viral capsid with the host cell is sufficient to 
activate the pathways leading to inflammatory responses (Muruve 2004). Mechanisms of 
innate immunity are either constitutively active or are activated very rapidly after infection 
(prior to the development of adaptive immune responses) and serve three very important 
functions. First, as the initial host response, innate defences limit or prevent infection by 
rapidly eliminating microbes (clearance). Second, the effector components of innate immunity 
interact and work together with components of adaptive immunity to synergistically augment 
microbial clearance. Third, innate immunity stimulates and can reprogram adaptive immune 
mechanisms to optimize clearance of specific types of microbes. The principal effector 
components of innate immunity involved in the clearance of microbes during in vivo infection 
include phagocytic and natural killer (NK) cells, cytokines, and complement (Zaiss, Machado 
et al. 2009). 
The innate recognition process is initiated by pathogen recognition through a number 
of receptors in the intracellular and extracellular compartments (Girardin, Sansonetti et al. 
2002; Muruve, Petrilli et al. 2008). The best studied family of receptors consists of the Toll-
like receptors (TLRs). The recognition of pathogen-associated molecular patterns by innate 
receptors triggers the activation of inflammatory genes, which serves to control the infection 
locally and recruit effector leukocytes to the site of infection (Girardin, Sansonetti et al. 
2002). The effector cells include granulocytes, natural killer (NK) cells, and 
monocytes/macrophages that perform cytolytic functions and secrete more cytokines/ 
chemokines to further amplify the immune response (Guidotti and Chisari 2001). 
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Figure 8. General overview of the innate response to adenovirus vectors. A number of different cell types are 
transduced and activated by Ad vectors, including endothelial cells. Ad vectors induce numerous inflammatory 
genes (chemokines and cytokines), which play a role in recruiting and activating innate effector cells to the site 
of infection. In addition, genes that are involved in leukocyte trafficking (such as adhesion molecules) are also 
expressed. Cytokine induction also occurs in innate effector cells such as dendritic cells and macrophages, 
further amplifying the response; adapted from: (Muruve 2004).  
 
 
Innate immune response depends both on adenovirus species and the dose. Innate immune 
responses to the virus can also be a major hurdle for long-term gene expression and oncolytic 
potency. Within 24 h, the virus induced inflammatory response eliminates about 80 % of the 
adenoviral particles (Worgall, Wolff et al. 1997), a number which  can be decreased by means 
of genetic modification.  
 
7.2. Adaptive immunity 
The hexon, being the major adenovirus capsid component, is a principal player in establishing 
the adaptive immune response – both humoral and cellular. The humoral and cellular immune 
response to recombinant adenoviral vectors, as described in several animal models,  result in 
the extinction of transgene expression, severe local inflammation, and production of anti-
adenovirus neutralizing antibodies (NAbs) that prevent readministration (Yang, Li et al. 
1995). Hexon capsid can have at least nine hypervariable loops, and some of these appear to 
function as type specific neutralizing antigens and thus define the serotype (Russell 2009). 
The expression of adenoviral genes results in an immune response specifically directed 
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against the products of these genes. The adaptive response is far weaker with last-generation 
vectors, which are characterized by the deletion of all or part of the viral genes.  
The adaptive response is thought to require the integration of both adenovirus specific 
memory CD4+ and cytotoxic CD8+ T cell responses. Adenovirus specific cytotoxic T 
lymphocytes (CTLs) are preferentially directed towards conserved epitopes within the virus 
capsid (mostly hexon protein) and kill infected cells (using multiple mechanisms that include 
perforin, Fas-L and TNFα). CTLs disrupt the adenovirus life cycle before progeny viruses are 
assembled (Leen, Christin et al. 2008).  
Immune modulatory agents can be used in combination with oncolytic viruses to 
enhance viral spread, transgene expression and antitumoral efficacy. Cyclophosphamide has 
recently been successfully used in combination with oncolytic adenovirus in animal studies to 
suppress regulatory T cell (Treg) induction and decrease tumor infiltration by immune cells 
(Di Paolo, Tuve et al. 2006; Lamfers, Fulci et al. 2006). Clinical studies are needed to 
evaluate the effect in cancer patients who often have pre-existing immunosupression caused 
by the disease and chemotherapy.  
 
7.3 Immunological obstacles to systemic administration 
Even though some encouraging results have been obtained, the efficacy of systemically 
administrated oncolytic adenovirus has been somewhat limited in updated clinical trials (Reid, 
Warren et al. 2002). It seems likely that there are number of different mechanisms for virus 
neutralization, e.g. aggregation of virus may impede proper recognition at the cell surface, and 
there is also evidence that virus–antibody complexes can enter the cell and that inhibition 
occurs at a later stage (Varghese, Mikyas et al. 2004). Following systemic administration, 
virus uptake by tumor cells is hampered by systemic antiviral immune response, for example 
due to the complement and NAbs. As practically all adults have been exposed to the most 
widely used serotype 5 adenovirus (Ad5), the immune system is primed to rapidly produce 
NAbs on re-exposure. A direct correlation between NAb and block of readministration of 
vector has been established by passive transfer of serum from treated to naïve animals (Yang, 
Li et al. 1995). After genetic manipulation, the virus often becomes attenuated and thus even 
more prone to immune response before massive oncolysis takes place. A high NAb titer may 
not limit local injection, but it can compromise systemic delivery. In this context, transient 
removal of pre-existent antibodies by immunoapheresis prior to virus treatment has been 
suggested (Chen, Yu et al. 2000). In data obtained in immune-competent mice, changing of 
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the adenovirus fiber knob allowed the virus to overcome the neutralizing activity of the pre-
existing NAbs (Sarkioja, Pesonen et al. 2008). This is supported by earlier observations where 
anti-adenovirus humoral immune defences against repeat adenovirus vector administration 
were circumvented by changing the adenovirus serotype (Mastrangeli, Harvey et al. 1996). 
Inducing immunological tolerance, or the use of polyethylene glycol (PEG), are other 
examples of how pre-existing antibodies can be partially overcome (Kass-Eisler, Leinwand et 
al. 1996; O'Riordan, Lachapelle et al. 1999). Transient immunosupression during initial 
administration of adenovirus can be used to prevent a rise in antibody titer, but it would not be 
expected to suppress the levels of pre-existing antibodies (Chen, Yu et al. 2000). 
There are also studies suggesting that pre-existing immunity does not necessarily 
reduce the efficacy of an oncolytic virus. On the contrary, it has been reported that the 
oncolytic effect of modified HSV is enhanced in HSV-1 seropositive mice, possibly due to 
interferon (IFN) -γ mediated tumor cell killing (Zhu, Su et al. 2007). It was also recently 
shown that anti-tumor efficacy of intratumorally injected adenovirus in mice was increased by 
pre-immunisation against adenovirus despite the production of NAbs (Tuve, Liu et al. 2009).  
After intravenous administration to mice, within minutes Ad vectors are 
predominantly sequestered by the liver (Shayakhmetov, Li et al. 2004) through hepatic 
macrophage (Kupffer cell) uptake (Tao, Gao et al. 2001) and hepatocyte transduction 
(Connelly 1999). Liver sequestration greatly reduces the ability of the virus to reach other 
tissues, and provokes toxic responses (Worgall, Wolff et al. 1997; Alemany, Suzuki et al. 
2000). The clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, 
natural antibodies, and complement (Xu, Tian et al. 2008).  
Once opsonised by plasma proteins, such as coagulation factors, hepatocytes are 
infected  in a CAR and integrin independent manner (Alemany and Curiel 2001). Coagulation 
factor IX (FIX) and complement component C4-binding protein (C4BP) can bind the Ad fiber 
knob domain and provide a bridge for virus uptake through hepatocellular HSPGs and low-
density lipoprotein (LDL)-receptor-related protein. Kupffer cell sequestration of Ad particles 
is likewise heavily dependent on Ad association with FIX and C4BP (Shayakhmetov, Gaggar 
et al. 2005). Another coagulation factor, FX, was recently found to bind directly not to fiber, 
but to the central depression of the hexon. Binding affinity of FX to Ad is high compared to 
other blood factors, and results in efficient hepatocyte transduction (Kalyuzhniy, Di Paolo et 
al. 2008; Waddington, McVey et al. 2008). Also vitamin K-dependent coagulation factors 
have been reported to opsonise adenovirus and facilitate the transduction of hepatocytes 
(Parker, Waddington et al. 2006), and vitamin K dependent coagulation factor synthesis 
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inhibition in mice with warfarin has been reported to reduce transduction to liver, spleen and 
lung (Koski, Rajecki et al. 2009).  
Systemic Ad administration is associated with thrombocytopenia, a phenomena shown 
to be dose-dependent, saturable and reversible. After systemic administration, Ad5 rapidly 
binds to circulating platelets, which causes their activation/aggregation and subsequent 
entrapment in liver sinusoids. Virus-platelet aggregates are taken up by the Kupffer cells and 
degraded. Ad sequestration in organs can be reduced by platelet depletion prior to vector 
injection (Stone, Liu et al. 2007). Depletion of the Kupffer cells by GdCl3 has also been done 
in vivo, which resulted in increased viraemia (Alemany, Suzuki et al. 2000). Preinjecting 
polyinosinic acid poly(I), a ligand for scavenger receptor,  has been used to reduce the 
Kupffer cell uptake and increase the circulating half-life of adenovirus in vivo (Ranki, 
Kanerva et al. 2007; Haisma, Kamps et al. 2008). In conclusion, considering the main 
immune response related problems, preventing anti-adenovirus NAbs or redirecting virus 
particles away from liver may make the virus more applicable for systemic use. 
 
8. Cancer stem cells and oncolytic adenoviruses 
 
 Stem cells characteristics include asymmetric replication, capacity for self-renewal, 
pluripotency and the proliferative ability to drive continued expansion of the cell population. 
Cells with stem cell-like attributes have been isolated from haematological malignancies and 
from several solid tumor types. These cells are thought to be responsible for the initiation and 
growth of tumors, and have been commonly referred to as cancer stem cells (CSCs) or cancer-
initiating cells (CICs). For tumors in which cancer stem cells play a role, at least three 
scenarios are possible (Figure 9). First, mutation of a normal stem cell or progenitor cell may 
create a cancer stem cell, which will then generate a primary tumor. Second, during treatment 
with chemotherapy, the majority of cells in a primary tumor may be destroyed, but if the 
cancer stem cells are not eradicated, the tumor may regrow and cause a relapse. Like their 
normal counterparts (Dean, Fojo et al. 2005; Rich 2007), putative cancer stem cells show 
remarkable resistance to radiation and chemotherapy (Reya, Morrison et al. 2001). Their 
capacity for surviving apparently curative treatment can result in tumor relapse. Third, cancer 
stem cells arising from a primary tumor may emigrate to distal sites and create metastatic 
lesions (Jordan, Guzman et al. 2006). 
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Figure 9. The role of cancer stem cells in tumor initiation, relapse and metastasis. A, mutated stem cell or 
progenitor cell may create a tumor initiating cancer stem cell. B, a relapse after seemingly successful 
chemotherapy may be caused by cancer stem cells refractory to the treatment. C, once detaching from the 
primary tumor, cancer stem cells may relocate to distant sites and initiate metastases; adapted from: (Jordan, 
Guzman et al. 2006) 
 
 
Oncolytic viruses enter cells through infection and may therefore be resistant to defence 
mechanisms exhibited by the cancer stem cells, such as efflux pumps and defective apoptotic 
signalling (Coukos, Makrigiannakis et al. 2000). Oncolytic adenoviruses can be engineered to 
attack CSCs by utilizing linage specific cell surface markers, dysfunctional stem cell-
signalling pathways, or upregulated oncogenic genes (Ribacka, Pesonen et al. 2008). Indeed, 
oncolytic viruses are the first approach shown to be effective against tumor-initiating cells 
(Ribacka and Hemminki 2008). However, mesenchymal stem cells are known to express 
CAR poorly, suggesting that lack of CAR may constitute an overall problem for infectivity of 
stem cells. Capsid-modified adenoviral vectors are able to overcome CAR deficiency for 
effective gene delivery to mesenchymal stem cells (Mizuguchi, Sasaki et al. 2005; 
Hakkarainen, Sarkioja et al. 2007), breast cancer CSCs (Eriksson, Guse et al. 2007) and brain 
tumor CSCs (Jiang, Gomez-Manzano et al. 2007). Another possible approach to 
transductionally target oncolytic adenovirus towards CSCs is to use single chain monoclonal 
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antibodies or other bispecific adapter molecules through which the virus can attach to a 
specific cell surface protein (Dmitriev, Kashentseva et al. 2000).  
Fiber modified Δ24-mutated oncolytic adenoviruses have been shown to kill 
differentiated breast cancer cells in vitro, and to abrogate human breast cancer stem cell 
derived tumor growth in vivo (Eriksson, Guse et al. 2007; Bauerschmitz, Ranki et al. 2008). In 
addition, viruses may be engineered to express therapeutic transgenes that specifically target 
properties that CSCs rely upon for self-renewal and cell division. 
 
9. Preclinical combination therapy 
 
Because of the unique mode of tumor destruction, oncolytic virotherapy has the potential to 
augment the antineoplastic activity of chemotherapy and radiation therapy. Oncolytic 
adenoviruses do not have cross-resistance with existing treatments, and therefore tumors 
resistant to other therapies may be susceptible to adenoviral therapy (Kanerva, Zinn et al. 
2003). Further, the side effects caused by the adenovirus treatments differ from the ones 
caused by chemotherapeutics or radiation therapy. Therefore, by combining conventional 
therapies with virus treatments, it is possible to reach additive or synergistic effect without 
increased side effects (Raki, Sarkioja et al. 2008).  
First promising preclinical treatment studies combining oncolytic adenovirus with 
chemotherapy were done with ONYX-015 and cisplatin. Human xenograft bearing mice 
received ONYX-015 intratumorally or intravenously, with or without concurrent 
chemotherapy. Subsequent anti-tumor efficacy in the group receiving combination treatment 
was significantly greater than in the groups receiving either agent alone (Heise, Sampson-
Johannes et al. 1997). In work done with lung cancer cell lines and primary cultures freshly 
made from lung cancer patients, ONYX-015 was reported to work synergistically also with 
paclitaxol and cisplatin (You, Yang et al. 2000). Another report showing antitumor synergy 
resulted from studying prostate cancer-specific adenovirus CV787 in combination with 
paclitaxel and docetaxel in xenograft bearing mice (Yu, Chen et al. 2001). In another study, 
recombinant adenovirus containing the thymidine kinase (TK) gene driven by the osteocalcin 
promoter was highly selective in blocking the growth of osteosarcoma in experimental 
models, when delivered concurrently with acyclovir (Cheon, Ko et al. 1997). Further evidence 
of the benefits of combination treatments was provided by studying the α-fetoprotein-specific 
35 
 
adenovirus CV890 in combination with doxorubicin in mice. Following the treatment, 
hepatocellular carcinoma liver xenografts were eliminated (Li, Yu et al. 2001).  
Combining radiation therapy with oncolytic adenoviruses is an intriguing approach, 
since adenoviral E1A protein has been implicated in the potentiation of apoptosis induced by 
various external stimuli, including radiation. Ad5 E1A sensitizes cells to radiation-induced 
apoptosis by inhibiting NF-kappaB activity (Shao, Karunagaran et al. 1997). Preclinical 
studies combining the E1B-deleted, replication-competent ONYX-015 with radiation also led 
to enhanced oncolysis beyond that of either monotherapy both in vitro and in vivo (Rogulski, 
Freytag et al. 2000). Synergistic potential of combining radiation therapy with oncolytic 
adenovirus Ad5-Δ24RGD was revealed in glioma xenograft mouse model. Tumor regression 
occurred in all mice, resulting in long-term survival without evidence of tumor regrowth 
(Lamfers, Grill et al. 2002). Later, the experiment was repeated and even though combined 
treatment with Ad5-Δ24RGD and irradiation was reported to show enhanced antitumor 
activity in subcutaneous glioma xenografts, it did not work in an orthotopic glioma model 
(Lamfers, Idema et al. 2007). These discrepant results are a reminder of the importance of 
finding the suitable animal model when assessing the effects of combination therapies with 
oncolytic adenoviruses. Encouraging preclinical findings have also led to clinical trials, some 
of which will be discussed in the following chapter. 
 
10. Clinical use of oncolytic viruses 
 
Cancer has become the most treated disease with means of gene therapy (Edelstein, Abedi et 
al. 2004). This is in part due to the intrinsic oncolytic nature of some viruses. The first reports 
describing tumor regressions concomitant with naturally acquired virus infections dates to the 
mid-1800s (Sinkovics and Horvath 1993). Reported early cases were often patients with 
haematological malignancies, known to be associated with severely compromised 
immunological state. Remissions following natural virus infections were more often seen in 
young patients, and were short-lived and incomplete (Kelly and Russell 2007). The earliest 
clinical testing began properly in the mid-1900s. The clinical studies performed at that time 
were unsafe, as therapeutic material administered to patients often consisted of infectious 
body fluids or infected tissue harvested from patients with ongoing virus infections. In 1949, 
Hepatitis B virus was used in a clinical trial in which the patients suffering from Hodking‟s 
disease were treated with virus containing sera or tissue extracts. Some of the patients showed 
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improvement lasting at least one month, but also severe side effects were reported, leading to 
the death of one patient (Hoster, Zanes et al. 1949).  Flaviviruses such as West Nile are spread 
by mosquitoes and exceedingly common in Egypt. A clinical trial with Egypt 101 (early 
passage West Nile) was enrolled in the early 50‟s for the treatment of advanced, unresponsive 
neoplasms. Responses were rare, and cases of encephalitis were reported concomitant with 
the treatment (Southam and Moore 1952). Also in the 50‟s, adenoidal-pharyngeal-conjuctivis 
virus (APC), now known to be an adenovirus, was used to treat cervical carcinoma, and 
localized tumor necrosis was frequently seen (Huebner, Rowe et al. 1956; Georgiades, 
Zielinski et al. 1959). In the early 70‟s, a large clinical trial was launched using non-
attenuated mumps viruses to treat 18 types of tumors. Delivery methods varied from 
intravenous to oral administration utilizing virus containing bread or pieces of tampon. Rectal 
administration was also used. The results were among the best yet seen in oncolytic virus 
trials, with encouraging response rate and minimal toxicity (Asada 1974). In the 70‟s and 
80‟s, regulatory barriers led to huge decrease in the number of reported clinical trials 
employing oncolytic viruses, and the need for diminished pathogenic potential had become 
evident.  
Later on, recombinant technology enabled the modification of oncolytic viruses to 
become more selective for tumor cells, and thus safer to use. The new era with genetically 
engineered oncolytic viruses started in the early 1990‟s with the use of herpes simplex virus 
type one (HSV-1) in an experimental glioma model (Martuza, Malick et al. 1991). Five years 
later, E1B 55K gene-deleted ONYX-015 (Reid, Warren et al. 2002) established clinical proof-
of-concept for oncolytic virotherapy in the first Phase I trial in which the virus was directly 
injected into head and neck tumors (Ganly, Kirn et al. 2000). ONYX-015 was well tolerated 
and showed localized efficacy in head and neck cancer trials as a single agent (Nemunaitis, 
Ganly et al. 2000). Only patients with advanced incurable cancers were initially enrolled. 
Once tentative safety was demonstrated, treatment of patients with premalignant conditions 
followed (Ries and Korn 2002). Finally, ONYX-015 became the first virus to undergo clinical 
trials combined with chemotherapy. Promising effects were obtained on localized head and 
neck tumors following direct injection combined with systemic cisplatin and 5-fluorouracil 
(5-FU) chemotherapy (Khuri, Nemunaitis et al. 2000). This was the first trial in history to 
demonstrate combined oncolytic virus and chemotherapy combination efficacy. A phase III 
clinical trial of head and neck carcinoma in combination with chemotherapy was halted in the 
US prematurely because of funding problems in 2003.  After this, H101, oncolytic adenovirus 
similar to ONYX-015, was constructed in China. In addition to modified E1B-55KD, it has 
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partial E3 deletion of the Adenovirus Death Protein. In 2005, H101 was approved for treating 
advanced nasopharyngeal carcinoma in combination with chemotherapy (regimen of 5-FU + 
cisplatin), and became the first oncolytic virus product approved by a governmental agency 
for human use (Yu and Fang 2007). The efficacy of combining H101 with chemotherapeutics 
was comparable to the efficacy obtained previously in the phase II trial combining ONYX-
015 with chemotherapeutics (Khuri, Nemunaitis et al. 2000). While ONYX-015 is well 
tolerated and shows activity when injected intratumorally, it is inefficient as a single agent. It 
has also failed targeting metastases when administrated systemically (Crompton and Kirn 
2007). 
The first published clinical trial reporting results of radiation therapy combined with 
an oncolytic virus, was a phase I trial using replicating adenovirus, Ad5-CD/TK, which has an 
E1B-deletion and carries a fusion gene expressing two prodrug-activating enzymes, 
Escherichia coli cytosine deaminase and HSV-TK. Virus in combination with a prodrug 
therapy (5-FC and valganciclovir) and radiation resulted in significant reduction in prostate-
specific antigen (PSA) tumor marker level (Freytag, Stricker et al. 2003).  
Transcriptionally controlled viruses with cancer specific TSP driven E1A have also 
been well tolerated in patients (DeWeese, van der Poel et al. 2001). The same applies to 
transcriptionally targeted oncolytic adenovirus expressing immunostimulatory cytokine GM-
CSF. Phase I trial with CG0070 in recurrent bladder cancer was launched in 2005. Minimal 
toxicity was reported and the trial was expanded to a multiple-dose trial which is still 
ongoing. No clinical trials have yet been completed with targeted Ads, but we can expect 
some to be reported within the near future. A trial with Ad5-Δ24RGD was launched in 2004 
for the treatment of ovarian cancer, and in 2007 for the treatment of recurrent glioblastoma.  
A number of trials have revealed a proof of principle for oncolytic adenovirus 
replication in tumors. Importantly, the safety profile of these viruses has been encouraging. 
Side effects, mostly flu-like symptoms and transient hepatotoxicity, were tolerable even after 
systemic application of high virus titers (Reid, Warren et al. 2002; Ko, Hawkins et al. 2005). 
Although individual tumor responses were observed, the overall therapeutic efficacy of 
oncolytic adenovirus monotherapy needs to be improved. Clinical experiences to date suggest 
that short-term potential for this class of therapeutics lies in combination therapy regimens. 
Increasing potency of the vectors by means of arming, detargeting, retargeting, and coating of 
adenoviruses is necessary to improve the delivery of the agent to the treatment site.  
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AIMS OF THE STUDY 
 
 
1. To evaluate different capsid modified adenoviruses in their transduction and oncolytic 
efficiency in gastric and pancreatic cancer cells, tissues and xenografts (I, III-IV). 
 
2. Determine activity of oncolytic adenoviruses armed with tissue-specific promoters in 
CD44
+
CD24
-/low
 breast cancer cells from pleural effusions of breast cancer patients 
(II). 
 
3. To study release kinetics and stability of a silica embedded adenovirus in vitro and in 
vivo, and use of silica implants for intraperitoneal virus delivery in mice bearing 
orthotopic gastric or pancreatic cancer (III-IV). 
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MATERIALS AND METHODS 
 
 
1. Cell lines  
All cell lines used in the studies are listed below (table 1). Cell lines were cultured as 
recommended by the supplier, and the culturing conditions are described in more detail in the 
studies I-IV. 
 
Table 1. Human cell lines used in this study. 
 
Cell line Description Source Study 
911 Transformed human embryonic retinoblasts ATCC
1
 II 
293 Transformed embryonic kidney cells ATCC
1
  I-IV 
A549 Lung adenocarcinoma cells ATCC
1
 I-IV 
KatoIII Diffuse gastric cancer ATCC
1
 I 
Hs 766T 
 
Lymph node methastasis of pancreatic cancer ATCC
1
 IV 
 
SW 1990 
 
Spleen methastasis of pancreatic cancer ATCC
1
 IV 
 
Capan-2 Pancreatic adenocarsinoma ATCC
1
 IV 
HPAC Pancreatic adenocarsinoma ATCC
1
 IV 
Panc-1 Pancreatic epithelial carcinoma ATCC
1
 III-IV 
MKN-1 Adenosquamous gastric cancer Dr. Hiroshi Yokozaki
2
 I 
MKN-7 Intestinal gastric cancer Dr. Hiroshi Yokozaki
2
 I 
MKN-28 Intestinal gastric cancer Dr. Hiroshi Yokozaki
2
 I, III 
MKN-74 Intestinal gastric cancer Dr. Hiroshi Yokozaki
2
 I 
MKN-45 Diffuse gastric cancer Dr. Hiroshi Yokozaki
2
 I 
JIMT-1 Breast cancer cell line, phenotypically of epithelial 
progenitor cell origin 
Dr. J. Isola
3
 II 
1
Cell line purchased from Amercan Type Culture Collection (ATCC) 
2
Cell line is a gift from Dr. Hiroshi Yokozaki (Kobe University, Kobe, Japan) 
3
Cell line is a gift from Dr. Minna Tanner (University of Tampere and Tampere University Hospital, Tampere, 
Finland) 
 
2. Fresh human cells and tissues 
Informed consent from the patient and permission for studies on human tissue from the ethics 
committee were obtained prior to the experiments. Fresh liver samples were received from 
donor livers that were to be transplanted into recipients (Department of Surgery, Helsinki 
University Central Hospital). For slicing, infecting and culturing the liver slices, see study I. 
Fresh gastric (I) and pancreatic (IV) cancer samples were obtained from cancer patients 
undergoing surgery in Department of Surgery, Helsinki University Central Hospital. See the 
corresponding studies for details of processing, infecting and culturing of the tumor tissue. 
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Primary adult human skin fibroblasts (HSFs) (III) were established from a skin punch biopsy 
obtained from the arm of a healthy male volunteer (age 27). 
3. Adenoviruses 
Wild type adenovirus Ad300wt was purchased from ATCC (Manassas, VA, USA). All 
recombinant adenoviruses are listed in table 2. Ad5/3ala-Δ24, Ad5/3mdr-E1, Ad5/3mdr-Δ24 
and Ad5/3-hTERT-Δgp were cloned as described in study II. Replicating and replication-
deficient adenoviruses were amplified on A549 and 293 cells, respectively. Viruses were 
purified from cell extracts on double caesium chloride gradients. VP titer was measured at 
260 nm, and the amount of infectious particles was determined by standard TCID50 or plaque 
assay on 293 cells. The presence of gene insertions and deletions were confirmed with 
polymerase chain reaction (PCR) and sequencing. 
 
 
Table 2. Recombinant adenoviruses used in this study. All viruses represent serotype 5. 
Virus E1 Fiber Used in Reference 
Ad5luc1  Luciferase Wild type I, IV (Kanerva, Mikheeva 
et al. 2002) 
Ad5/3luc1  
 
Luciferase 5/3 serotype chimerism I, III-
IV 
(Kanerva, Mikheeva 
et al. 2002) 
Ad5lucRGD  
 
Luciferase RGD motif in HI loop I, IV (Dmitriev, Krasnykh 
et al. 1998; Wu, Seki 
et al. 2002) 
Ad5(GL)  
 
GFP + luciferase Wild type I, IV (Wu, Seki et al. 
2002) 
Ad5.pK7  
 
GFP + luciferase 7 lysine residues at C-
terminus 
I, IV (Wu, Seki et al. 
2002) 
Ad5RGD.pK7  
 
GFP + luciferase RGD motif in HI loop and 
7 lysine residues at C-
terminus 
I, IV (Wu, Seki et al. 
2002) 
Ad5LacZ  
 
LacZ Wild type I (Yotnda, Zompeta et 
al. 2004) 
Ad5pK21LacZ  
 
LacZ 21 lysine residues at C-
terminus 
I (Yotnda, Zompeta et 
al. 2004) 
RadlacZ Replaced with 
CMV promoter 
driven lacZ 
Wild type III (Wilkinson and 
Akrigg 1992) 
RAd66 Deleted Wild type III (Wilkinson and 
Akrigg 1992) 
AdlacZ216 Deleted, replaced 
with β-  galactosi- 
dase cDNA
3
 
Wild type III (Laitinen, Mäkinen 
et al 1998) 
Ad5/3-Δ24  
 
Δ241 5/3 serotype chimerism I-IV (Kanerva, Zinn et al. 
2003) 
Ad5-Δ24RGD  
 
Δ241 RGD motif in HI loop I, III-
IV 
(Suzuki, Fueyo et al. 
2001) 
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Ad5-Δ24E3
2 
 
Δ241 Wild type I, IV (Suzuki, Fueyo et al. 
2001) 
Ad5/3ala-Δ24 α-Lactalbumin 
promoter, Δ241 
5/3 serotype chimerism II (Bauerschmitz, 
Ranki et al. 2008) 
Ad5/3mdr-E1 Multidrug 
resistance protein 
promoter 
5/3 serotype chimerism II (Bauerschmitz, 
Ranki et al. 2008) 
Ad5/3mdr-Δ24 Multidrug 
resistance protein 
promoter, Δ241 
5/3 serotype chimerism II (Bauerschmitz, 
Ranki et al. 2008) 
Ad5/3-hTERT-Δgp Telomerase 
promoter, Δ241 
5/3 serotype chimerism II (Bauerschmitz, 
Ranki et al. 2008) 
Ad5/3-Cox2L-Δ24 Cyclo-oxygenase 2 
promoter, Δ241 
5/3 serotype chimerism II (Bauerschmitz, Guse 
et al. 2006) 
Ad5/3-
Δ24hCGβ4 
Δ241 5/3 serotype chimerism III (Rajecki, Kanerva et 
al. 2007) 
Ad5/3-Δ24-TK-
GFP 
Δ241 5/3 serotype chimerism III (Raki, Hakkarainen 
et al. 2007) 
1 
24 bp deletion in constant region 2 of E1A 
2
 The virus has an intact E3 region, therefore it was originally named Ad5-Δ24E3 
3 
Nuclear-targeted β-galactosidase cDNA under a β-actin promoter and a cytomegalovirus (CMV) enhancer 
4 
Transgene for the beta-chain of human chorionic gonadotropin (hCGbeta) replaces the gp19K reading frame, 
but most of  the E3region remains intact 
 
4. In vitro studies 
4.1 Isolating CD44
+
CD24
-/low
 cell populations (II) 
Cells from pleural effusion samples and JIMT-1 cells were sorted with FITC-labeled anti-
CD44 and phycoerythrin-labeled anti-CD24 antibodies as described in study II. 
4.2 Gene expression analysis (II) 
To predict the activity of different promoter constructs in CD44
+
CD24
-/low 
cells,
 
the 
messenger RNA from sorted JIMT-1 cells was isolated. Expression levels of α-lactalbumin 
(ala), cyclo-oxygenase 2 (Cox-2), telomerase (hTERT) and multidrug resistance protein (mdr) 
were normalized to highly expressed house keeping gene β-actin. For the materials and RT-
PCR conditions, see study II. 
4.3 Release and infectivity of silica-embedded virus (III) 
Silica gels were allowed to melt in buffer to study the degradation kinetics by measuring the 
Si content at different time points. Simultaneous release of adenovirus was measured with 
quantitative PCR and with TCID50 to quantify the functionality of the released virus. 
To study the effect of long term storage on functionality of the silicated virus, viability 
of the silica embedded β-galactosidase producing adenovirus was studied after incubating for 
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229 days at +4
o
C. To test the stability of silicated viruses at 37
o
C, β-galactosidase producing 
virus was embedded in silica and incubated in phosphate-buffered saline (PBS) for up to 32 
days. In both cases, silica monoliths were then placed to cell cultures. After incubation cells 
were stained for β- or X-galactosidase to show the presence of functional viruses. 
4.4 Marker gene transfer assays (I-IV)  
To study the effects of the capsid modifications on gene transfer, cancer cells (I-II, IV) and 
CAR-positive nonmalignant 293 cells (I, IV), as well as gastric (I) and pancreatic cancer 
tissues (IV), were infected with replication deficient capsid modified viruses. In addition, one 
sample representing normal pancreatic tissue was analyzed (IV). Luciferase or β-gal assays 
were done to measure transgene activity. In tissue samples, protein concentrations were 
measured and included in the analysis as an internal control. In biodistribution analysis (I, 
III), mouse organs were snap-frozen at collection. The tissue samples were analyzed for 
transgene expression and protein content as with the clinical samples. For more detailed 
protocols, see „Materials and Methods‟ from the respective studies. 
4.5 Cytotoxicity assay (I-II, IV) 
To compare the cell killing efficacy of oncolytic viruses, cell lines were infected with three 
different doses and followed for cytopathic effect. The most pronounced differences in 
viability of the cells infected with different viruses are seen when the most oncolytic viruses 
have killed most of the cells at 1 VP per cell. At that time point, the mitochondrial activity of 
the cells was measured with MTS assay. 
4.6 Quantification of infectious particles in tissue samples (I, III) 
To determine the amount of infectious particles in mouse organs, tissues were snap-frozen at 
collection. The tissue samples were homogenized and standard TCID50  test was done. To 
study the adenoviral replication in human liver, human liver precision-cut slices were infected 
with oncolytic and control viruses. The number of infectious particles was determined by the 
TCID50 at different time points. 
 
5.  In vivo studies 
Three to four week old female mice were obtained from Taconic (Ejby, Denmark) and were 
quarantined for two weeks before starting the experiments. Animal experiments were 
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approved by the Experimental Animal Committee of the University of Helsinki and the 
Provincial Government of Southern Finland. 
5.1 Biodistribution of capsid-modified viruses in orthotopic gastric cancer 
model (I). 
To study the effects of capsid modifications on gene transfer in vivo, an orthotopic gastric 
cancer model was established. After eight days, capsid modified replication-deficient viruses, 
and the virus with the unmodified capsid, were injected intarperitoneally. Tumors and normal 
organs were collected 48 hours after the injection and luciferase or lacZ activity was 
measured from tissue homogenates as described above.  
5.2 Silica biodegradation and release of functional virus in vivo (III). 
Silica gel implants with LacZ-viruses were implanted subcutaneously into mice. Histological 
samples from tissue surrounding the implant were collected at selected time points and 
stained with X-gal to study the functionality of the virus released from the implants. Release 
of the functional virus from the silica was further assessed in intraperitoneal models. 
Orthotopic gastric cancer bearing mice received oncolytic GFP producing adenovirus as an 
intraperitoneal injection or in a silica implant. Tumors were collected at selected time points 
and stained with a GFP-specific antibody.  
To study the effects of the silica implant on gene delivery efficacy and persistence of 
viral replication, orthotopic pancreatic cancer tumors were established. In this study, we 
utilized oncolytic adenovirus which secretes hCGβ that can be quantified from the blood. 
Mice received the virus either in a silica implant or as an injection. At selected time points, 
hCGβ was measured from the blood and selected organs were collected to analyze the amount 
of infectious particles with TCID50. 
5.3 Antibody formation against adenovirus delivered within or without 
silica (III, IV) 
Silica implants containing adenovirus were implanted subcutaneously into C57Bl mice. 
Serum was collected at selected time points to measure anti-adenoviral antibodies with EIA 
(III). To study the effects of silica implant on the virus-induced NAb response, ICR mice 
were given Ad5/3-Δ24 as an injection or in a silica implant. Sera were collected 28 days after 
treatment, and NAbs were analyzed with gene transfer inhibition assay. Briefly, Ad5/3luc1 
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was mixed with different serum dilutions, and the effect on gene transfer was assayed on 293 
cells. Reduction in luciferase activity reflects the amount of NAbs in the serum (IV). 
5.4. Adenovirus induced pro-inflammatory cytokines (IV) 
To study whether delivering the virus in silica implant affects innate toxicity, ICR mice were 
given Ad5/3-Δ24 either intraperitoneally or in silica implant. 6 hours post treatment, sera 
were collected to analyze early pro-inflammatory cytokines IL-6, IFN-γ and RANTES. 
5.5 Survival experiments (I-IV) 
An orthotopic gastric cancer model was established to study the effect of oncolytic virus 
capsid modifications on survival. MKN-28 cells were injected intraperitoneally into SCID 
mice. Ten days later, mice were treated with a panel of viruses as a single intraperitoneal 
injection, and the mice were followed for survival. In the same experiment, serum samples for 
hCGβ were collected from the tail vein 50 days after injecting the cells to see if the tumor 
burden would correlate with the upcoming survival results (I). 
To study the anti-tumor activity of tissue specific promoters in CD44
+
CD24
-/low
 cell 
originating tumors, sorted JIMT-1 cells were injected into the topmost mammary fat pads of 
nude mice. Intratumoral virus injections were performed thrice a week for a total of 5 weeks, 
and the tumor growth was followed throughout the experiment. In the same experiment, 
expression of CD44 and CD24 in tumors was measured by flow cytometry (II). 
To find out if silica embedded virus can prolong the survival of the orthotopic tumor 
bearing mice, silica implant was studied as intraperitoneal virus delivery device in studies III 
and IV. In study III, Orthotopic pancreatic cancer tumors were grown in SCID mice before 
treatment with Ad5/3-Δ24 in silica implants. Control mice were treated with silica implants 
without virus, and mice were followed for survival. In the study IV, we studied silica implant 
in the context of peritoneally disseminated pancreatic cancer. Mice were treated with a panel 
of capsid modified oncolytic adenoviruses or wild type Ad300wt and followed for survival. 
To represent the standard-of-care in the treatment of pancreatic cancer, a group receiving 
gemcitabine intraperitoneally was included and compared to a group receiving gemcitabine in 
combination with Ad5/3-Δ24. In addition, silica gel was used in delivery of Ad5/3-Δ24 and 
compared to the virus injected group. 
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6. Statistical analysis (I-IV) 
Two-tailed Student‟s t test was used to compare the differences between viruses and their 
control groups. Survival was analyzed according to Kaplan-Meier with SPSS 11.5 for 
Windows (I-IV). In the in vivo survival experiment based on the subcutaneous tumor growth, 
a nonparametric change-point test was used to determine a systematic change in the pattern of 
observations as opposed to chance. Proc Mixed was used to examine the effects of group and 
time on tumor growth. Pair comparisons were performed so that each group was individually 
compared with all other groups in the experiment (II). 
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RESULTS AND DISCUSSION 
 
 
1. Capsid modified adenoviruses show enhanced transduction to gastric and 
pancreatic cancer cells and tissues (I, IV) 
 
One limiting factor in the clinical performance of the adenoviral (Ad) vectors may be 
attributed to their broad native tropism. Thus there is a need for the derivation of Ad agents 
that have the capacity for intrinsic, self-directed, specific localization to the disease-affected 
target tissue. Limiting factor for the most frequently used serotype 5 adenoviruses (Ad5) is 
dependence on the coxsackie- and adenovirus receptor (CAR), which is variably expressed in 
most advanced cancers (Bauerschmitz, Barker et al. 2002). Native Ad5 tropism can be 
modified to circumvent CAR deficiency in cancer cells. Transductional targeting of 
adenoviruses, e.g. by incorporating targeting moieties into the fiber knob region,  aims at the 
enhanced transduction of the target cell (Glasgow, Everts et al. 2006). For instance, 
incorporation of Arg-Gly-Asp (RGD)-containing peptide in the HI loop of the fiber knob 
allows the virus to utilize αvβ-class integrins for binding and internalization (Dmitriev, 
Krasnykh et al. 1998).  These integrins are highly expressed in gastric and pancreatic cancers 
(Kawashima, Tsugawa et al. 2003; Grzesiak, Ho et al. 2007).  Adenoviruses with a COOH-
terminal polylysine tail are retargeted to bind to heparan sulfates (Wu, Seki et al. 2002; 
Yotnda, Zompeta et al. 2004).  Substitution of the entire fiber knob was used in the 
construction of Ad5/3, an Ad5 vector that features a chimeric fiber with the adenovirus 
serotype 3 (Ad3) knob domain (Kanerva, Mikheeva et al. 2002). This virus binds to Ad3 
receptor, which is yet not characterized.   
In this work we compared these capsid modifications in terms of increasing the transduction 
efficacy to gastric and pancreatic cancer cells and tissues. Capsid modifications were found to 
increase gene transfer to the gastric and pancreatic cancer cell lines, whereas in CAR-positive 
nonmalignant 293 cells the effect was less than 7-fold (figure 1 in study I and figure 1 in 
study IV). In intestinal type gastric cancer cell lines, capsid modification with pK21 
modification, with tail of 21 lysines in COOH-terminus, displayed the best gene transfer 
efficacy (up to 479-fold compared to the wild type capsid). In the diffuse-type cell lines, in 
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addition to pK21 modification, also pK7 (with 7 lysines in COOH terminus) resulted in over 
70-fold enhancement in gene transfer efficacy, and these viruses also performed best in the 
adenosquamous gastric cancer cells. With RGD- and 5/3 modified viruses, the results 
remained less impressive, but they also enhanced gene transfer to some extent. Further, capsid 
modifications increased gene transfer to primary gastric cancer specimens (figure 2 in study 
I), in which 5/3 and RGD modified viruses were overall most efficient with up to 256- and 
198-fold increase, respectively. As the cell lines are derived from different origins, it was not 
completely unexpected to see a different profile of gene transfer in comparison with the cell 
lines. 
In pancreatic cancer cell lines, 5/3 modified virus was superior to others with as high 
as 95 000 fold increase in gene transfer. Impressive results were also obtained with RGD-
modified virus, with 22 000-fold increase. Of the polylysine tail containing viruses, only pK7 
was studied and was evaluated to be at best 67 more efficient than the unmodified capsid. 
These results correlated nicely with the ones obtained from the clinical pancreatic cancer 
samples (figure 2 in study IV), 5/3 modification increasing gene transfer in all cancer tissue 
samples up to 18 000-fold. The second best virus had RGD modification, which augmented 
gene transfer up to 7600-fold. Importantly, capsid modifications did not increase transduction 
to normal pancreatic tissue. Given that clinical cancer samples displayed inter-sample 
variation, it might be of interest to analyze the tumor before selecting a virus for the 
treatment. 
To assess transductional efficacy in different organs, in vivo biodistribution analysis 
was performed in an orthotopic gastric cancer model resembling human metastatic disease 
(figure 3 in study I). 5/3 and pK7 modifications increased gene transfer to intraperitoneally 
disseminated tumors, but 5/3 modification also increased gene transfer to other organs. Since 
liver toxicity is a concern in the context of adenoviral gene therapy (Worgall, Wolff et al. 
1997; Connelly 1999), it was important to discover that neither virus increased hepatic gene 
transfer.  
We conclude that adenoviruses with capsid modifications transducer gastric and 
pancreatic cancer cells and tissues significantly better than viruses with wild type capsid. 
Since the rationale behind transductional targeting via genetic modifications is based on 
ubiquitous properties shared by most tumor cells, the abovementioned capsid modifications 
have proved powerful in other types of cancers as well. 5/3 virus for instance has been 
successfully used in transductional targeting in glioma (Zheng, Ulasov et al. 2007), ovarian 
(Kanerva, Zinn et al. 2003), cervical (Kanerva, Lavilla-Alonso et al. 2008), kidney (Guse, 
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Diaconu et al. 2009), renal (Guse, Ranki et al. 2007), breast (Stoff-Khalili, Stoff et al. 2005), 
prostate (Rajecki, Kanerva et al. 2007) and gallbladder cancer model (Tekant, Davydova et al. 
2005).  Next, we sought to find out whether the enhanced transductional efficacy would 
translate into enhanced anti-cancer activity of oncolytic viruses. 
 
2. Improving oncolytic effect in vitro and in vivo with capsid modified 
adenoviruses (I, IV) 
 
The efficacy of oncolytic adenoviruses is linked to the infection of target cells and subsequent 
productive replication. Most human tumors, including gastric and pancreatic cancers, are 
deficient in the retinoblastoma/p16 pathway (Fueyo, Gomez-Manzano et al. 2000; Heise, 
Hermiston et al. 2000; Hernando, Nahle et al. 2004). Δ24-mutated adenoviruses have a 24 bp 
deletion in constant region 2 of E1A, in which the pRb binding domain resides. Via this 
domain, wild-type E1A binds to and activates pRb, required for replication in normal cells. In 
cancer cells, Δ24 is complemented by the inactivation of pRb by p16/Rb pathway defects, 
enabling virus replication (Sherr 1996). We used oncolytic viruses with the Δ24 backbone to 
find out which capsid modification in combination with Δ24 would be the most potent in 
killing gastric and pancreatic cancer cells. We also wanted to study whether the same viruses 
would display enhanced anti-tumor activity in mice.  
In cell killing assay on gastric (figure 4 in study 1) and pancreatic cancer cell lines 
(figure 3 in study IV), Ad5/3-Δ24 was overall the most potent. The same virus was the best 
in increasing the survival of mice bearing orthotopic gastric (figure 5a in study 1) and 
pancreatic cancer tumors (figure 4a in study IV). In gastric cancer model, also RGD-
modified virus prolonged the survival significantly. In the same model, serum hCG-β 
concentration, a prognostic factor in patients with gastric cancer (Louhimo, Kokkola et al. 
2004), was lower in mice treated with oncolytic viruses (figure 5b in study 1), possibly a 
further indication of true anti-tumor efficacy. As mentioned above, the same capsid 
modifications have proved useful in many cancer types, and as an example, clinical trials with 
Ad5-Δ24RGD are ongoing for the treatment of ovarian cancer and recurrent glioblastoma.  
To study replication of oncolytic viruses in human liver, human liver explants were 
infected with unmodified, RGD, or 5/3-modified oncolytic viruses, and the wild type virus 
(figure 6 in study 1). No true replication was detected, since the amounts of infectious 
particles in the culture increased 4-fold at best over the whole period of 48h. This was an 
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important finding, since liver may be the main organ in the context of adenovirus associated 
toxicity (Worgall, Wolff et al. 1997; Connelly 1999). In conclusion, we saw that capsid 
modified oncolytic viruses improved antitumor efficacy in gastric and pancreatic cancer 
models in vitro and in vivo, but no replication was detected in human livers. Further 
preclinical studies will need to be done to evaluate safety, but after this is done, these viruses 
might be valuable for treating gastric or pancreatic cancers in humans. 
 
3. Transductional and transcriptional targeting to CD44
+
CD24
-/low
 cells (II) 
3.1 Tissue-specific promoters are active in CD44
+
CD24
-/low
 breast cancer 
cells 
It has been proposed that human tumors contain stem cells that have a central role in tumor 
initiation and post-treatment relapse. Putative breast cancer stem cells may reside in the 
CD44
+
CD24
-/low
 population (Al-Hajj, Wicha et al. 2003; Hill and Perris 2007; Kelly, Dakic et 
al. 2007). As adenoviruses are not subject to the typical mechanisms of drug resistance such 
as drug efflux pumps and defective cell cycling (Coukos, Makrigiannakis et al. 2000), they 
might have potential in targeting cancer stem cells, known to be resistant to chemotherapy 
and radiation (Jordan, Guzman et al. 2006). We utilized capsid modified luciferase expressing 
viruses to investigate if gene transfer to CD44
+
CD24
-/low
 cells could be improved. 5/3 
modification seemed to be the optimal capsid configuration as it allowed 10-fold higher gene 
transfer to CD44
+
CD24
-/low
 cells. Based on this and a previous report describing 5/3 
modification to be efficient in targeting breast cancer initiating cells (Eriksson, Guse et al. 
2007), for further experiments we chose to construct viruses with 5/3 chimeric fibers. 
Oncolytic viruses can be transcriptionally targeted by utilizing tumor-specific promoters 
(TSP), which are active only in target cells. In normal cells adenovirus replication is 
prevented in the absence of  E1A expression (Saukkonen and Hemminki 2004). To identify 
which TSPs would be feasible in targeting breast cancer initiating cells, we extracted 
CD44
+
CD
24-/low 
cells from pleural effusions of breast cancer patients. As there were no 
previous reports on which promoters might be useful in the context of cancer stem cells, we 
chose tumor-specific promoters previously used in adenoviral gene therapy approaches. α-
lactalbumin (ala) (Li, Zhang et al. 2005), cyclo-oxygenase 2 (Cox-2) (Yamamoto, Alemany et 
al. 2001), telomerase (hTERT) (Horikawa, Cable et al. 1999), and multidrug resistance 
protein (mdr) (Walther, Wendt et al. 1997) promoters were introduced in luciferase producing 
5/3 chimeric adenoviruses to compare promoter activities in CD44
+
CD24
-/low
 cells (figure 
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1a). Mdr showed the strongest activity in pleural effusion cells. Highly specific activity was 
also achieved with hTERT promoter. The activity of Cox-2 was near to highly active CMV 
promoter. Expression with ala is too low for the successful control of oncolytic adenoviruses. 
Taken together these results suggested that mdr, hTERT, and Cox-2 promoters are active in 
CD44
+ +
CD24
-/low
 breast cancer cells, which encouraged us to find out whether oncolytic 
viruses featuring these tumor specific promoters would be efficient in killing breast cancer 
initiating cells.  
3.2. Tissue-specific promoters are useful in killing CD44
+
CD24
-/low
 breast 
cancer cells in vitro and in vivo  
Capsid modified Δ24 type oncolytic adenoviruses have previously been described to kill 
breast cancer initiating cells (Eriksson, Guse et al. 2007). As replication and toxicity of 
oncolytic viruses may be targeted via tumor specific promoters, we rationalized that such a 
virus could be targeted against breast cancer initiating cells. For transcriptional control, all our 
oncolytic viruses harbor the Δ24-bp deletion in E1A. Dual transcriptional control would be 
useful in the context of non-tumor cells in which the TSP is active. For example, normal 
tissue stem cells might express hTERT or mdr. Nevertheless, they would be expected to be 
intact in the Rb-p16 pathway. Thus in many cases, an Rb binding site deletion was included in 
the constructs (figure 1c).  
When CD44
+
CD24
-/low
 cells from pleural effusions were infected, we found that all 
5/3 modified viruses were more oncolytic than the wild-type Ad5 control (figure 2): In 2 out 
of 3 samples, Ad5/3-mdr-Δ24 was most oncolytic, with Ad5/3-hTERT-Δgp and Ad5/3-
Cox2L-Δ24 closely following. Despite the use of a TSP, these viruses were sometimes more 
potent than Ad5/3-Δ24. Adding the Rb binding site deletion to Ad5/3-mdr-E1A to make 
Ad5/3-mdr-Δ24 did not reduce the activity of the virus but actually increased potency. 
JIMT-1 is breast cancer derived cell line phenotypically of epithelial progenitor cell 
origin (Tanner, Kapanen et al. 2004). CD44
+
CD24
-/low
 sorted JIMT-1 cells were used for cell 
killing assay to look at the kinetics of cell killing between the different viruses (Figure 3a). 
Ad5/3-mdr-Δ24 and Ad5/3-hTERT-Δgp were the most effective TSP viruses and similar in 
the efficacy with the control virus Ad5/3-Δ24.  
To assess antitumor efficacy in vivo, CD44
+
CD24
-/low–derived tumors were 
established and injected with oncolytic viruses, all of which resulted in significantly smaller 
tumor size versus mock controls (Figure 4a). Ad5/3-Cox2L-Δ24 and Ad5/3-mdr-Δ24 showed 
the greatest antitumor efficacy and Ad5/3-mdr-Δ24 was superior when compared to control 
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virus Ad5/3-Δ24. Despite promising activity in vitro, Ad5/3-hTERT-Δgp was less effective in 
vivo than Ad5/3-Δ24. 
In conclusion, oncolytic adenoviruses controlled by the TSPs were able to kill 
CD44
+
CD24
-/low
 cells. These findings may have relevance for the elimination of cancer stem 
cells in humans, reducing relapse rates and improving long-term outcome for patients with 
breast cancer. As drug-resistant tumor initiating cells have been reported to exist in a 
perivascular niche, intravenous administration of an oncolytic virus might be highly effective 
to reach this site (Calabrese, Poppleton et al. 2007). Capsid modified viruses capable for dual 
transcriptional control, such as Ad5/3-mdr-Δ24 and Ad5/3-Cox2L-Δ24, may be appealing for 
clinical testing. However, it will be important to ensure that these treatments do not adversely 
affect the function of normal tissue stem cells. Development of such innovative strategies to 
target cancer stem cell populations in human malignancies is likely to increase treatment 
success. 
 
4. Quantification of putative stem cells in tumors originating from 
CD44
+
CD24
-/low 
cells (II) 
Putative stem cells divide asymmetrically. At each division, one or both daughter cells retain 
the same biological properties as the parent cell. Since the other daughter cell can also 
become a progenitor cell, a mutated progenitor could divide to produce differentiated tumor 
cells (Jordan, Guzman et al. 2006). To study this hypothesis, CD44
+
/CD24
-/low
 tumors were 
established and treated with Ad5/3mdr-Δ24 (able to kill CD44+/CD24-/low cells in vitro), or 
Ad5/3-ala-Δ24 (not able to kill CD44+/CD24-/low cells in vitro), followed by fluorescence-
activated cell sorting (FACS) (figure 4c). Interestingly, while Ad5/3mdr-Δ24 reduced tumor 
size (figure 4b), it also reduced the total number of CD44
+
/CD24
-/low
 cells, implying that the 
viruses also kill tumor-initiating cells, in accordance to what was seen in vitro. If viruses had 
only killed differentiated tumor cells, the proportion of CD44
+
CD24
_/low
 cells would have 
been higher, not lower, in virus versus mock-treated tumors. The proportion of CD44
+
/CD24
-
/low
 cells in the tumor returned to the same level as before cell
 
sorting, suggesting that 
asymmetrical cell division does occur.  
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5. Characterisation of silica implants for adenovirus preservation and 
release in vitro (III) 
 
Since one major obstacle in the cancer gene therapy remains to be the level and persistence of 
gene delivery to sufficiently large areas of the tumor, it was of interest to characterize a new 
viral delivery method for intraperitoneally disseminated disease. Silica sol-gel polymers (the 
name referring to solvent to gel-transition during polymerization) have many characteristics 
that make it interesting for drug delivery, and they have been successfully used for spatially 
controlled, prolonged delivery of different drugs (Coradin, Boissiere et al. 2006). Since also 
large proteins have been moulded in silica implants (Viitala, Jokinen et al. 2007), we 
hypothesized that they might be applicable also in adenovirus gene therapy. First we studied 
the utility of silica gel implants for their capability to store and release functional virus. In 
theory, high water content might disturb structural homogeneity of the implant in long term 
storage. However, the water in which the implant is stored is rapidly saturated by SiO2, 
stabilizing the implant from degradation (Jokinen, Koskinen et al. 2007). We therefore 
speculated, that silicated viruses might remain encapsulated and infective for long time.  
Steady release kinetics of smaller molecules and proteins from silica sol-gels has 
previously been described (Coradin, Boissiere et al. 2006; Viitala, Jokinen et al. 2007). Our 
work was the first to report biochemical properties and release kinetics of the silica-virus 
matrix. Nearly linear virus release as a function of time was detected (figure 1c), encouraging 
us to further study whether comparable kinetics could be obtained in vivo. We also found the 
virus stay infective for weeks at +37
o
C (figure 2a) and months at +4
o
C (table 1), which may 
facilitate their storage and distribution. The current guideline in storing the virus requires a -
80
o
C freezer, which is inconvenient for clinical use, for example. Retaining infectivity +37
o
C 
would be crucial in in vivo applications, where virus is embedded within the implant for long 
periods while slow degradation of the implant and concomitant virus release take place under 
physiological conditions. 
 
6. In vivo release and antitumor efficacy of virus in silica implants (III-IV) 
 
Since the in vitro results of virus preservation and release from the silica were encouraging, 
we wanted to study silica implants further for delivery of Ad to advanced orthotopic gastric 
and pancreatic cancer tumors in vivo. The implant can with a minor surgical procedure be 
placed subcutaneously, or intraperitoneally. First we confirmed in vivo gene transfer with 
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replication deficient reporter gene expressing viruses. Subcutaneously implanted LacZ-virus 
resulted in reporter gene expression in subcutaneous space (figure 2b in study III). Similarly, 
luciferase gene expression was detected in selected organs after intraperitoneal delivery of 
luciferase expressing virus (figure 3 in study III). Next, capsid-modified oncolytic viruses 
were implanted into the very vicinity of an intraperitoneal tumor, and extended release of 
functional viruses was seen. The results were confirmed with immunohistochemical stainings 
of the tumor (figure 2c in study III). We also utilized hCGβ-expressing Ad5/3-Δ24hCGβ for 
indirect quantification of replication from the blood (figure 4c in study II), since replication 
of this virus is tightly linked to the secretion of hCGβ (Rajecki, Kanerva et al. 2007). For 
comparison, we collected tumors and livers at the same time points for direct quantification of 
infectious virus particles (figures 4a and 4b in study II). Indeed, hCGβ-levels in the virus 
injected mice peaked at the same time point when highest amounts of infectious virus were 
detected in the organs (2 days after treatment). In the silica treated mice, both hCGβ-levels 
and virus replication displayed protracted kinetics, hCGβ peaking at day 7 and viral loads 
peaking days later. hCGβ levels stayed elevated even when there was no detectable 
replicating virus in the liver (3 weeks after treatment). At this time, pronounced replication 
was still ongoing in the tumor according to pfu-quantification, and thus at this time it seems 
likely that the elevated hCGβ levels were resultant of replication in the tumor. 
Treating pancreatic cancer bearing mice with virus implanted virus doubled the survival 
compared to the non-treated mice (figure 4d in study III). Since only combining adenoviral 
cancer gene therapy with standard therapy has yielded positive efficacy data in randomized 
phase 3 trials (Yu and Fang 2007; Pan, Zhang et al. 2009), and since gemcitabine remains the 
global standard-of-care for advanced pancreatic cancer (Bernhard, Dietrich et al. 2008), we 
included gemcitabine group to study if combination treatment with gemcitabine and virus 
would bring synergy or additional effect. In mice that received both gemcitabine and Ad5/3-
Δ24, median survival was longer than in the mice receiving gemcitabine only. There was a 
statistically non-significant trend for survival benefit in the combination treated mice when 
compared to mice receiving virus only. The modest survival benefit might be partially 
explained by the fact that gemcitabine reduces the rate of Ad5/3-Δ24 replication early after 
infection (Raki, Kanerva et al. 2005). However, it should not affect the total yield of the virus. 
There are also previously published studies implying that even when virus treatment or 
chemotherapy alone are effective, their combination is not, as in the case of doxorubicin and 
Ad5-Δ24RGD in primary osteosarcoma cells (Graat, Witlox et al. 2006). Still, we speculate 
that gemcitabine in combination with Ad5/3-Δ24 may be potent in treating pancreatic cancer, 
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but further work would need to be done to optimize the in vivo protocol. A previously 
described work utilizing the same drugs in ovarian cancer model implies that finding the 
optimal timing for delivery of the two drugs, either separately or at the same time, may proof 
critical (Raki, Kanerva et al. 2005).  
Silica embedded virus was as good as the direct virus injection in prolonging the survival, and 
thus the overall lower level of gene transfer with the implant did not compromise the anti-
tumor efficacy in survival experiments. Seeing superior survival benefit by the use of silica 
implant would have been unexpected because of the distinct virus release kinetics from the 
silica. Parameters such as dosing, timing and gel composition would require optimization to 
demonstrate true survival benefit of the silica implanted virus compared to virus injection. We 
still speculate that it might be obtainable for instance through lower virus doses and changing 
the gel composition to reach the optimal release kinetics. Still, our hypothesis that the release 
kinetics and possible shielding effect of the silica molecules surrounding the capsid would 
affect virus-induced immune response proved to be worth studying. 
 
7. Silica implants and anti-adenovirus immune response (III-IV) 
Since the release kinetics of the implanted virus are different from virus given as single 
intraperitoneal injection, we also wanted to study whether silica implant affects anti-viral 
immune response. Neutralizing antibody (NAb) response has been reported to limit 
readministration of the virus (Bierman, Crile et al. 1953; Chen, Yu et al. 2000; Tsai, Johnson 
et al. 2004). We hypothesized, that the use of silica implant might attenuate or postpone 
antibody formation.  
When the virus was given in a subcutaneous implant, the development of anti-
adenovirus antibodies was indeed slower than in the subcutaneously virus injected mice, in 
which the amount of antibodies was statistically significantly higher already a week before 
antibodies were even detected in the implant group (figure 4e in study III). A similar pattern 
was seen in an intraperitoneal model: When the virus was delivered in an intraperitoneal 
implant, virus induced NAb response was low compared to the mice receiving intaperitoneal 
virus injection (figure 6b in study IV). NAbs were analyzed at the time point when the titers 
are expected to have reached their peak values (Sarkioja, Pesonen et al. 2008). In the virus 
implant group, the NAb titers were at least a magnitude lower than in the virus injected mice. 
Lowered antibody formation against the delivered virus might be useful for facilitating 
readministration. Although the tumor environment may be relatively immune privileged, 
55 
 
peritumoral and systemic viral dissemination might be more effective if the antibody 
induction is lower. Lower NAb titers may also be crucial in safe readministration of 
adenovirus, since in mice viral toxicity caused by vector challenge is reported to be greater in 
preimmunized animals (Vlachaki, Hernandez-Garcia et al. 2002; Varnavski, Calcedo et al. 
2005). It was also of interest to find out whether intraperitoneal virus delivery would lead into 
a more favourable biodistribution when silica implant is used in preimmunized animals. In the 
presence of NAbs, the virus in silica implants resulted in more favourable pancreas to liver 
transduction profile (figures 5a and 5c in study IV). Again, liver transduction was 
significantly lower in the mice receiving the virus in silica implant, which may reduce toxicity 
(Worgall, Wolff et al. 1997; Connelly 1999; Tao, Gao et al. 2001). 
We hypothesized further that silica implant might also have an effect on virus-induced 
proimflammatory cytokine response critical for early viral toxicity (Raper, Chirmule et al. 
2003). After receiving a large dose of virus intraperitoneally, IL-6 was found to be lower 6 h 
after the treatment in the silica implant group vs. the injected ones (figure 6a in study IV), 
IFN-γ and RANTES displaying a similar pattern. These results suggest that co-administration 
of the virus with silica may partly prevent early viral toxicity, thus enabling administration of 
larger doses and/or more immunogenic viruses, if needed. 
As a conclusion, the data received from the immunological studies suggests that silica 
implant might be a way to partially overcome the problems associated with high 
immunogenicity of the virus, further broadening the safety/efficacy window of 
intraperitoneally administered oncolytic adenoviruses.  
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SUMMARY AND CONCLUSIONS 
 
 
The overall goal of this thesis was to improve the treatment options for incurable cancers 
using oncolytic adenoviruses, and capsid modified adenoviruses proved to be useful for 
transductional targeting to cancer cell lines and clinical tumor samples, as well as targeting 
for cancer initiating cells. More favorable in vivo biodistribution was also achieved with 
capsid modified adenoviruses. Furthermore, enhanced oncolytic potency was seen in vitro, 
which translated into improved anti-tumor effect in vivo. 5/3 chimerism emerged as the 
approach-of-choice in all studies, covering models of gastric, pancreatic and breast cancer. 
Importantly, the capsid modifications did not increase gene transfer to normal human 
pancreatic tissue, nor did the oncolytic capsid modified viruses replicate in normal human 
liver tissue ex vivo. 
To gain strict transcriptional targeting to breast cancer initiating CD44
+
CD24
-/low
 cells, 
we inserted TSPs in the genome of capsid modified Δ24-based oncolytic viruses to control 
expression of E1A and subsequent replication. Cox-2, hTERT and mdr promoters proved 
useful in the in vitro studies, displaying even better oncolytic potential in CD44
+
CD24
-/low
 
cells isolated from the pleural effusion samples than the highly active control virus without 
the TSP. Compared to the conventional oncolytic viruses, all of the viruses armed with TSPs 
were superior in eradicating tumors in mice. In conclusion, oncolytic adenoviruses controlled 
by the TSPs seem to be able to kill CD44
+
CD24
-/low
 cells.  
The biochemical properties of silica sol-gel implant proved to be favorable for 
preserving the virus in different temperatures, and functional virus release correlated with the 
degrading of the silica-virus matrix. Utilizing orthotopic gastric and pancreatic cancer models, 
we found the silica implant to steadily release replication competent virus also in vivo, 
resulting in a lower level but more sustained replication in the tumor tissue. Intraperitoneal 
delivery also resulted in a more favorable biodistribution of the virus, with less virus 
accumulating in the liver. The survival benefit gained with the silica implant was comparable 
to the intraperitoneally injected virus. Silica gel-based virus delivery lowered toxicity 
mediating proimflammatory cytokine response, and production of total and anti-adenovirus 
neutralizing antibodies (NAbs). Further, silica shielded the virus against pre-existing NAbs, 
resulting in more favorable biodistribution in the preimmunized mice. In this thesis book we 
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describe adenovirus capsid modifications and TSPs that enhance safety, specificity and anti-
tumor activity of oncolytic adenoviruses. Furthermore, new delivery methods, such as the 
studied silica implant, might further broaden the safety window and/or gene transfer efficacy 
of intraperitoneally administrated oncolytic adenoviruses. 
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